

Frederick R Appelbaum

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3276278/frederick-r-appelbaum-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

823
papers

44,515
citations

102
h-index

203
g-index

904
ext. papers

49,923
ext. citations

5.8
avg, IF

6.9
L-index

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 823 | Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <i>Blood</i> , 2017 , 129, 424-447 | 2.2 | 2764 |
| 822 | Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <i>Blood</i> , 2010 , 115, 453-74 | 2.2 | 2483 |
| 821 | Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. <i>Blood</i> , 2001 , 97, 3390-400 | 2.2 | 1183 |
| 820 | Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. <i>New England Journal of Medicine</i> , 1986 , 314, 729-35 | 59.2 | 1113 |
| 819 | Reduced mortality after allogeneic hematopoietic-cell transplantation. <i>New England Journal of Medicine</i> , 2010 , 363, 2091-101 | 59.2 | 1102 |
| 818 | Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. <i>New England Journal of Medicine</i> , 2017 , 377, 454-464 | 59.2 | 1067 |
| 817 | Age and acute myeloid leukemia. <i>Blood</i> , 2006 , 107, 3481-5 | 2.2 | 941 |
| 816 | All-trans-retinoic acid in acute promyelocytic leukemia. <i>New England Journal of Medicine</i> , 1997 , 337, 1021-8 | 59.2 | 895 |
| 815 | Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , 2000 , 343, 1750-7 | 59.2 | 840 |
| 814 | Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. <i>New England Journal of Medicine</i> , 2001 , 344, 175-81 | 59.2 | 831 |
| 813 | Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3244-54 | 2.2 | 733 |
| 812 | Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 301, 2349-61 | 27.4 | 612 |
| 811 | Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. <i>New England Journal of Medicine</i> , 1989 , 320, 197-204 | 59.2 | 552 |
| 810 | Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. <i>New England Journal of Medicine</i> , 1998 , 338, 962-8 | 59.2 | 541 |
| 809 | Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. <i>New England Journal of Medicine</i> , 1993 , 329, 1219-24 | 59.2 | 525 |
| 808 | Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. <i>New England Journal of Medicine</i> , 1998 , 339, 1649-56 | 59.2 | 506 |
| 807 | A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. <i>Blood</i> , 2013 , 121, 4854-60 | 2.2 | 441 |

| | | | |
|-----|---|------|-----|
| 806 | Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. <i>Blood</i> , 2011 , 117, 3214-9 | 2.2 | 420 |
| 805 | Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. <i>Lancet Oncology, The</i> , 2014 , 15, 986-96 | 21.7 | 410 |
| 804 | Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. <i>New England Journal of Medicine</i> , 1991 , 324, 1773-8 | 59.2 | 400 |
| 803 | Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. <i>Blood</i> , 2010 , 116, 4693-9 | 2.2 | 397 |
| 802 | All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. <i>Blood</i> , 2002 , 100, 4298-302 | 2.2 | 379 |
| 801 | Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. <i>Cancer</i> , 2005 , 104, 1442-52 | 6.4 | 364 |
| 800 | FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. <i>Blood</i> , 2001 , 97, 3589-95 | 2.2 | 361 |
| 799 | Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. <i>Blood</i> , 2002 , 100, 415-9 | 2.2 | 358 |
| 798 | Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. <i>Blood</i> , 2001 , 98, 3212-20 | 2.2 | 352 |
| 797 | Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. <i>Blood</i> , 2005 , 105, 49-53 | 2.2 | 349 |
| 796 | Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. <i>Blood</i> , 2003 , 102, 3447-54 | 2.2 | 346 |
| 795 | Haematopoietic cell transplantation as immunotherapy. <i>Nature</i> , 2001 , 411, 385-9 | 50.4 | 341 |
| 794 | Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. <i>Journal of Clinical Oncology</i> , 2007 , 25, 793-8 | 2.2 | 340 |
| 793 | Transplantation of Marrow Cells From Unrelated Donors for Treatment of High-Risk Acute Leukemia: The Effect of Leukemic Burden, Donor HLA-Matching, and Marrow Cell Dose. <i>Blood</i> , 1997 , 89, 4226-4235 | 2.2 | 334 |
| 792 | Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. <i>New England Journal of Medicine</i> , 1990 , 323, 705-12 | 59.2 | 326 |
| 791 | Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4246-54 | 2.2 | 320 |
| 790 | Hematopoietic-cell transplantation at 50. <i>New England Journal of Medicine</i> , 2007 , 357, 1472-5 | 59.2 | 319 |
| 789 | Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. <i>Blood</i> , 2001 , 97, 3380-9 | 2.2 | 312 |

| | | | |
|-----|---|------|-----|
| 788 | Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. <i>Journal of Clinical Oncology</i> , 2007 , 25, 799-804 | 2.2 | 296 |
| 787 | Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. <i>New England Journal of Medicine</i> , 1989 , 320, 828-34 | 59.2 | 277 |
| 786 | Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3249-56 | 2.2 | 273 |
| 785 | Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?. <i>Journal of Clinical Oncology</i> , 2016 , 34, 329-36 | 2.2 | 270 |
| 784 | Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1190-7 | 2.2 | 270 |
| 783 | Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. <i>Blood</i> , 2007 , 110, 4606-13 | 2.2 | 262 |
| 782 | Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1011-6 | 2.2 | 257 |
| 781 | Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 926-957 | 7.3 | 256 |
| 780 | Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. <i>Blood</i> , 2002 , 100, 1201-7 | 2.2 | 253 |
| 779 | Phase I Study of 131I-Anti-CD45 Antibody Plus Cyclophosphamide and Total Body Irradiation for Advanced Acute Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 1999 , 94, 1237-1247 | 2.2 | 253 |
| 778 | Cord-Blood Transplantation in Patients with Minimal Residual Disease. <i>New England Journal of Medicine</i> , 2016 , 375, 944-53 | 59.2 | 247 |
| 777 | Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4417-23 | 2.2 | 230 |
| 776 | Allogeneic hematopoietic stem cell transplantation for myelofibrosis. <i>Blood</i> , 2003 , 102, 3912-8 | 2.2 | 228 |
| 775 | Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. <i>Blood</i> , 2002 , 100, 48-51 | 2.2 | 227 |
| 774 | Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. <i>Blood</i> , 2007 , 109, 5136-42 | 2.2 | 226 |
| 773 | Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. <i>Blood</i> , 2012 , 119, 6198-208 | 2.2 | 217 |
| 772 | Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. <i>Blood</i> , 2004 , 103, 347-52 | 2.2 | 202 |
| 771 | The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. <i>British Journal of Haematology</i> , 2006 , 135, 165-73 | 4.5 | 196 |

| | | | |
|-----|---|------|-----|
| 770 | NCCN Clinical Practice Guidelines Acute myeloid leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 984-1021 | 7.3 | 194 |
| 769 | Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 721-749 | 7.3 | 191 |
| 768 | Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. <i>Blood</i> , 2010 , 115, 3869-78 | 2.2 | 188 |
| 767 | Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. <i>Blood</i> , 2007 , 109, 2791-3 | 2.2 | 187 |
| 766 | High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. <i>Blood</i> , 2002 , 99, 3158-62 | 2.2 | 187 |
| 765 | A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. <i>Blood</i> , 2019 , 133, 1548-1559 | 2.2 | 178 |
| 764 | Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. <i>Blood</i> , 2001 , 98, 988-94 | 2.2 | 176 |
| 763 | Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). <i>Experimental Hematology</i> , 2001 , 29, 448-57 | 3.1 | 173 |
| 762 | Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. <i>Blood</i> , 2003 , 102, 820-6 | 2.2 | 172 |
| 761 | High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. <i>Blood</i> , 2003 , 102, 2351-7 | 2.2 | 172 |
| 760 | Structural and functional alterations of FLT3 in acute myeloid leukemia. <i>Clinical Cancer Research</i> , 2009 , 15, 4263-9 | 12.9 | 169 |
| 759 | Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. <i>Blood</i> , 2008 , 111, 2563-72 | 2.2 | 166 |
| 758 | Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1258-64 | 2.2 | 163 |
| 757 | Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2859-67 | 2.2 | 163 |
| 756 | Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 355-65 | 4.7 | 155 |
| 755 | Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2745-2753 | 2.2 | 154 |
| 754 | Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. <i>Blood</i> , 2003 , 101, 3628-34 | 2.2 | 153 |
| 753 | Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. <i>Blood</i> , 2002 , 100, 3869-76 | 2.2 | 153 |

| | | | |
|-----|---|-----|-----|
| 752 | Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. <i>Transplantation</i> , 2001 , 72, 1924-9 | 1.8 | 152 |
| 751 | CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. <i>Blood</i> , 2007 , 109, 4168-70 | 2.2 | 150 |
| 750 | HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. <i>Blood</i> , 2003 , 102, 31-5 | 2.2 | 150 |
| 749 | Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1766-71 | 2.2 | 145 |
| 748 | Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3878-84 | 2.2 | 143 |
| 747 | A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. <i>Blood</i> , 2002 , 99, 2712-9 | 2.2 | 143 |
| 746 | Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1211-8 | 4.7 | 137 |
| 745 | Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Blood</i> , 2009 , 114, 5444-53 | 2.2 | 137 |
| 744 | The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. <i>Transplantation</i> , 1992 , 54, 829-33 | 1.8 | 136 |
| 743 | Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. <i>Annals of Internal Medicine</i> , 1984 , 101, 581-8 | 8 | 135 |
| 742 | 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. <i>Blood</i> , 2006 , 107, 2184-91 | 2.2 | 132 |
| 741 | Prolonged complete remission following high dose chemotherapy of Burkitt's lymphoma in relapse. <i>Cancer</i> , 1978 , 41, 1059-63 | 6.4 | 132 |
| 740 | Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. <i>Biology of Blood and Marrow Transplantation</i> , 2001 , 7, 39-44 | 4.7 | 131 |
| 739 | Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004 , 10, 320-7 | 4.7 | 126 |
| 738 | Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3194-201 | 2.2 | 124 |
| 737 | Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. <i>Blood</i> , 2003 , 101, 2521-8 | 2.2 | 124 |
| 736 | Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3611-21 | 2.2 | 121 |
| 735 | The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation. <i>Blood</i> , 2001 , 98, 1701-7 | 2.2 | 120 |

| | | | |
|-----|--|------|-----|
| 734 | Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. <i>Blood</i> , 2016 , 127, 1502-8 | 2.2 | 119 |
| 733 | Treatment of chronic granulocytic leukemia with chemoradiotherapy and transplantation of marrow from identical twins. <i>New England Journal of Medicine</i> , 1982 , 306, 63-8 | 59.2 | 117 |
| 732 | The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. <i>Blood</i> , 2012 , 119, 2657-64 | 2.2 | 116 |
| 731 | Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. <i>Blood</i> , 2012 , 119, 5591-8 | 2.2 | 113 |
| 730 | Acute myeloid leukemia, version 2.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 1047-55 | 7.3 | 113 |
| 729 | Thyroid function following hematopoietic cell transplantation in children: 30 years' experience. <i>Blood</i> , 2009 , 113, 306-8 | 2.2 | 110 |
| 728 | The current status of hematopoietic cell transplantation. <i>Annual Review of Medicine</i> , 2003 , 54, 491-512 | 17.4 | 109 |
| 727 | The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. <i>Blood</i> , 2007 , 109, 1782-9 | 2.2 | 108 |
| 726 | A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 495-505 | 4.7 | 108 |
| 725 | Thalidomide for treatment of patients with chronic graft-versus-host disease. <i>Blood</i> , 2000 , 96, 3995-3996 | 6.2 | 108 |
| 724 | Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. <i>Blood</i> , 2001 , 98, 3505-12 | 2.2 | 107 |
| 723 | Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. <i>Blood</i> , 2002 , 99, 2002-8 | 2.2 | 106 |
| 722 | High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1396-402 | 2.2 | 105 |
| 721 | Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. <i>Blood</i> , 2009 , 113, 2888-94 | 2.2 | 100 |
| 720 | Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. <i>British Journal of Haematology</i> , 1996 , 93, 59-67 | 4.5 | 100 |
| 719 | Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. <i>Annals of Internal Medicine</i> , 1990 , 112, 590-7 | 8 | 100 |
| 718 | Gemtuzumab ozogamicin for acute myeloid leukemia. <i>Blood</i> , 2017 , 130, 2373-2376 | 2.2 | 96 |
| 717 | Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3439-46 | 2.2 | 96 |

| | | | |
|-----|---|------|----|
| 716 | Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to | 2.2 | 94 |
| 715 | The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized | 2.2 | 93 |
| 714 | Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?. <i>Blood</i> , 2013 , 121, 2567-73 | 2.2 | 92 |
| 713 | Final adult height of patients who received hematopoietic cell transplantation in childhood. <i>Blood</i> , 2005 , 105, 1348-54 | 2.2 | 92 |
| 712 | US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL. <i>Blood Advances</i> , 2016 , 1, 250-259 | 7.8 | 91 |
| 711 | Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 908-15 | 4.7 | 91 |
| 710 | Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. <i>Blood</i> , 2009 , 113, 3383-91 | 2.2 | 87 |
| 709 | Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1157-64 | 2.2 | 86 |
| 708 | Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. <i>Blood</i> , 2007 , 109, 2999-3006 | 2.2 | 86 |
| 707 | Gemtuzumab ozogamicin: time to resurrect?. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3921-3 | 2.2 | 84 |
| 706 | Inadvertent transmission of a donor's acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia. <i>New England Journal of Medicine</i> , 1990 , 322, 1794-6 | 59.2 | 84 |
| 705 | Second allogeneic transplantation after failure of first autologous transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2000 , 6, 272-9 | 4.7 | 83 |
| 704 | Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. <i>Blood</i> , 2001 , 97, 2541-8 | 2.2 | 81 |
| 703 | Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 341-50 | 4.7 | 80 |
| 702 | Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. <i>British Journal of Haematology</i> , 2003 , 120, 281-8 | 4.5 | 80 |
| 701 | Nonbacterial nonfungal pneumonia following marrow transplantation in 100 identical twins. <i>Transplantation</i> , 1982 , 33, 265-8 | 1.8 | 80 |
| 700 | Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. <i>British Journal of Haematology</i> , 1989 , 72, 567-72 | 4.5 | 79 |
| 699 | Interstitial pneumonitis following autologous bone marrow transplantation. <i>Transplantation</i> , 1986 , 42, 515-7 | 1.8 | 79 |

| | | | |
|-----|--|------|----|
| 698 | Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. <i>JAMA Oncology</i> , 2017 , 3, 1675-1682 | 13.4 | 78 |
| 697 | Implementing a Death with Dignity program at a comprehensive cancer center. <i>New England Journal of Medicine</i> , 2013 , 368, 1417-24 | 59.2 | 76 |
| 696 | The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. <i>Blood</i> , 2004 , 103, 4276-84 | 2.2 | 76 |
| 695 | Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. <i>Blood</i> , 2013 , 121, 2424-31 | 2.2 | 75 |
| 694 | Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 573-84 | 4.7 | 75 |
| 693 | End points to establish the efficacy of new agents in the treatment of acute leukemia. <i>Blood</i> , 2007 , 109, 1810-6 | 2.2 | 74 |
| 692 | Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2134-41 | 2.2 | 72 |
| 691 | Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403. <i>Blood</i> , 2014 , 124, 796-796 | 2.2 | 72 |
| 690 | A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 465-71 | 4.7 | 71 |
| 689 | Allogeneic marrow transplantation in the treatment of preleukemia. <i>Annals of Internal Medicine</i> , 1984 , 100, 689-93 | 8 | 71 |
| 688 | Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors. <i>Haematologica</i> , 2014 , 99, 322-8 | 6.6 | 70 |
| 687 | Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia. <i>Blood</i> , 2005 , 105, 3749-56 | 2.2 | 69 |
| 686 | Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2011 , 155, 182-9 | 4.5 | 68 |
| 685 | Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2003 , 9, 472-81 | 4.7 | 68 |
| 684 | Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 4-7 | 4.7 | 66 |
| 683 | SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2014 , 165, 504-9 | 4.5 | 66 |
| 682 | Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. <i>Blood</i> , 2014 , 124, 287-95 | 2.2 | 66 |
| 681 | Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. <i>Blood</i> , 2001 , 98, 586-93 | 2.2 | 66 |

| | | | |
|-----|---|-----|----|
| 680 | Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study. <i>Blood</i> , 2002 , 100, 29-35 | 2.2 | 66 |
| 679 | A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2000 , 6, 25-34 | 4.7 | 65 |
| 678 | A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study. <i>Leukemia Research</i> , 1999 , 23, 787-94 | 2.7 | 65 |
| 677 | Phenotyping of canine lymphoma with monoclonal antibodies directed at cell surface antigens: classification, morphology, clinical presentation and response to chemotherapy. <i>Hematological Oncology</i> , 1984 , 2, 151-68 | 1.3 | 62 |
| 676 | Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma. <i>Blood</i> , 2018 , 132, 1011-1011 | 2.2 | 62 |
| 675 | Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. <i>British Journal of Haematology</i> , 1997 , 98, 1010-6 | 4.5 | 60 |
| 674 | Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 64, 289-301 | 6.1 | 59 |
| 673 | Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2002 , 8, 206-12 | 4.7 | 59 |
| 672 | Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. <i>Blood</i> , 2001 , 97, 2180-1 | 2.2 | 58 |
| 671 | Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. <i>Blood</i> , 2001 , 98, 3868-70 | 2.2 | 57 |
| 670 | Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2003 , 9, 206-12 | 4.7 | 57 |
| 669 | A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617. <i>Leukemia Research</i> , 2000 , 24, 567-74 | 2.7 | 56 |
| 668 | Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. <i>Blood</i> , 2017 , 129, 1763-1767 | 2.2 | 55 |
| 667 | Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. <i>Blood</i> , 2009 , 113, 866-74 | 2.2 | 55 |
| 666 | Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004 , 10, 552-60 | 4.7 | 55 |
| 665 | Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2002 , 8, 161-9 | 4.7 | 55 |
| 664 | Marrow transplant experience in children with acute lymphoblastic leukemia: an analysis of factors associated with survival, relapse, and graft-versus-host disease. <i>Medical and Pediatric Oncology</i> , 1985 , 13, 165-72 | | 54 |
| 663 | Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine. <i>American Journal of Medicine</i> , 1985 , 78, 978-83 | 2.4 | 54 |

| | | | |
|-----|---|-------|----|
| 662 | Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , 2020 , 135, 371-380 | 2.2 | 53 |
| 661 | Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. <i>Haematologica</i> , 2012 , 97, 1401-4 | 6.6 | 52 |
| 660 | Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. <i>Transplantation</i> , 1985 , 40, 162-6 | 1.8 | 52 |
| 659 | Treatment of hairy-cell leukemia with chemoradiotherapy and identical-twin bone-marrow transplantation. <i>New England Journal of Medicine</i> , 1982 , 307, 479-81 | 59.2 | 52 |
| 658 | Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2014 , 123, 2960-7 | 2.2 | 51 |
| 657 | Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 713-20 | 4.7 | 51 |
| 656 | The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 1996 , 46, 142-64 | 220.7 | 51 |
| 655 | Study of cell dose and storage time on engraftment of cryopreserved autologous bone marrow in a canine model. <i>Transplantation</i> , 1978 , 26, 245-8 | 1.8 | 51 |
| 654 | Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow. <i>Blood</i> , 2012 , 119, 2675-8 | 2.2 | 49 |
| 653 | Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2010 , 151, 430-4 | 4.5 | 49 |
| 652 | Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Leukemia Research and Treatment</i> , 2014 , 2014, 421723 | | 48 |
| 651 | Low relapse without excessive transplant-related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1122-9 | 4.7 | 48 |
| 650 | Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts. <i>Annals of Internal Medicine</i> , 2020 , 172, 229-239 | 8 | 48 |
| 649 | Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1363-8 | 4.7 | 47 |
| 648 | Twenty-four-color spectral karyotyping reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2000 , 28, 318-28 | 5 | 47 |
| 647 | Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2014 , 164, 223-32 | 4.5 | 46 |
| 646 | Cord blood transplantation for haematological malignancies: conditioning regimens, double cord transplant and infectious complications. <i>British Journal of Haematology</i> , 2009 , 147, 207-16 | 4.5 | 46 |
| 645 | Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries. <i>New England Journal of Medicine</i> , 1994 , 331, 1063-7 | 59.2 | 46 |

| | | | |
|-----|---|------|----|
| 644 | NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 19, 16-27 | 7.3 | 46 |
| 643 | Acute myeloid leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 280-317. | 7.3 | 45 |
| 642 | Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2010 , 115, 1288-95 | 2.2 | 45 |
| 641 | A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease. <i>Transplantation</i> , 1990 , 50, 49-54 | 1.8 | 45 |
| 640 | Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody. <i>Transplantation</i> , 1992 , 54, 844-51 | 1.8 | 44 |
| 639 | Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 559-64 | 4.7 | 42 |
| 638 | Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 531-7 | 4.7 | 42 |
| 637 | PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents by more than one mechanism. <i>Leukemia Research</i> , 2002 , 26, 91-106 | 2.7 | 42 |
| 636 | Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1523-32 | 1.9 | 41 |
| 635 | Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 345-54 | 4.7 | 40 |
| 634 | Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. <i>Leukemia Research</i> , 2004 , 28, 1177-80 | 2.7 | 40 |
| 633 | Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiation. <i>British Journal of Haematology</i> , 1996 , 92, 699-706 | 4.5 | 40 |
| 632 | Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 549-55 | 4.7 | 38 |
| 631 | Long-term survival after chemotherapy for acute myeloid leukemia. <i>Cancer</i> , 1997 , 80, 2199-2204 | 6.4 | 38 |
| 630 | Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2003 , 120, 1017-25 | 4.5 | 38 |
| 629 | FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. <i>Transplantation</i> , 1993 , 56, 800-7 | 1.8 | 37 |
| 628 | Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials. <i>Blood</i> , 2016 , 128, 763-73 | 2.2 | 37 |
| 627 | Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. <i>Leukemia</i> , 2019 , 33, 2599-2609 | 10.7 | 36 |

| | | | |
|-----|--|-----|----|
| 626 | Treatment of children with acute promyelocytic leukemia: results of the first North American Intergroup trial INT0129. <i>Pediatric Blood and Cancer</i> , 2009 , 53, 1005-10 | 3 | 36 |
| 625 | Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents. <i>Leukemia Research</i> , 1998 , 22, 221-39 | 2.7 | 36 |
| 624 | The problem of thrombocytopenia after hematopoietic stem cell transplantation. <i>Stem Cells</i> , 1996 , 14 Suppl 1, 261-73 | 5.8 | 36 |
| 623 | Prevalence of clinically relevant bacteremia after upper gastrointestinal endoscopy in bone marrow transplant recipients. <i>American Journal of Medicine</i> , 1990 , 89, 134-6 | 2.4 | 36 |
| 622 | Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3883-8 | 2.2 | 35 |
| 621 | Early mortality and overall survival of acute myeloid leukemia based on facility type. <i>American Journal of Hematology</i> , 2017 , 92, 764-771 | 7.1 | 34 |
| 620 | Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 697-702 | 4.7 | 34 |
| 619 | Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group clinical trial. <i>Cancer Investigation</i> , 2001 , 19, 603-10 | 2.1 | 34 |
| 618 | An update on allogeneic marrow transplantation for myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 1995 , 17, 95-9 | 1.9 | 34 |
| 617 | Combined immunosuppression with cyclosporine and methotrexate in dogs given bone marrow grafts from DLA-haploidentical littermates. <i>Transplantation</i> , 1984 , 37, 62-5 | 1.8 | 34 |
| 616 | Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1463-6 | 4.7 | 33 |
| 615 | SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016 , 128, 901-901 | 2.2 | 33 |
| 614 | Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1274-1280 | 4.7 | 32 |
| 613 | Allogeneic marrow transplantation following cyclophosphamide and escalating doses of hyperfractionated total body irradiation in patients with advanced lymphoid malignancies: a Phase I/II trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995 , 32, 1103-9 | 4 | 32 |
| 612 | Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. <i>British Journal of Haematology</i> , 2014 , 165, 497-503 | 4.5 | 31 |
| 611 | Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials. <i>Cancer</i> , 2013 , 119, 4170-9 | 6.4 | 31 |
| 610 | SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2014 , 167, 233-7 | 4.5 | 31 |
| 609 | Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy. <i>Blood</i> , 2008 , 111, 2261-8 | 2.2 | 31 |

| | | | |
|-----|---|-----|----|
| 608 | Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. <i>Leukemia Research</i> , 2000 , 24, 653-63 | 2.7 | 31 |
| 607 | Cure of malignant lymphoma in dogs with peripheral blood stem cell transplantation. <i>Transplantation</i> , 1986 , 42, 19-22 | 1.8 | 31 |
| 606 | Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 691-696 | 4.7 | 30 |
| 605 | The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011). <i>Leukemia and Lymphoma</i> , 2013 , 54, 252-4 | 1.9 | 30 |
| 604 | A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1088-92 | 4.7 | 30 |
| 603 | Trisomy 11: an association with stem/progenitor cell immunophenotype. <i>British Journal of Haematology</i> , 1995 , 90, 266-73 | 4.5 | 30 |
| 602 | Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. <i>Blood</i> , 2010 , 116, 5650-9 | 2.2 | 29 |
| 601 | Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2000 , 6, 321-6 | 4.7 | 29 |
| 600 | Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance). <i>Blood</i> , 2013 , 122, 3903-3903 | 2.2 | 29 |
| 599 | Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 848-54 | 4.7 | 28 |
| 598 | Hematopoietic cell transplantation with autologous cord blood in patients with severe aplastic anemia: an opportunity to revisit the controversy regarding cord blood banking for private use. <i>Pediatric Blood and Cancer</i> , 2011 , 56, 1009-12 | 3 | 28 |
| 597 | A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. <i>British Journal of Haematology</i> , 1992 , 80, 49-54 | 4.5 | 28 |
| 596 | Marrow transplantation for leukemia following fractionated total body irradiation. A comparative trial of methotrexate and cyclosporine. <i>Leukemia Research</i> , 1985 , 9, 1255-61 | 2.7 | 28 |
| 595 | Treatment of acute leukemia in adults with chemoradiotherapy and bone marrow transplantation. <i>Cancer</i> , 1985 , 55, 2202-9 | 6.4 | 28 |
| 594 | The Problem of Thrombocytopenia after Hematopoietic Stem Cell Transplantation. <i>Oncologist</i> , 1996 , 1, 371-380 | 5.7 | 28 |
| 593 | Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study. <i>Haematologica</i> , 2011 , 96, 914-7 | 6.6 | 27 |
| 592 | Gamma-irradiation of pretransplant blood transfusions from unrelated donors prevents sensitization to minor histocompatibility antigens on dog leukocyte antigen-identical canine marrow grafts. <i>Transplantation</i> , 1994 , 57, 423-6 | 1.8 | 27 |
| 591 | Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML. <i>Leukemia and Lymphoma</i> , 2004 , 45, 2409-17 | 1.9 | 25 |

| | | | |
|-----|---|------|----|
| 590 | Cytogenetic correlation with disease status and treatment outcome in advanced stage leukemia post bone marrow transplantation: a Southwest Oncology Group study (SWOG-8612). <i>Leukemia Research</i> , 1995 , 19, 381-8 | 2.7 | 25 |
| 589 | The somatostatin analog octreotide in the management of the secretory diarrhea of the acute intestinal graft-versus-host disease in a patient after bone marrow transplantation. <i>Transplantation</i> , 1990 , 49, 1194-5 | 1.8 | 25 |
| 588 | Marrow transplant studies in dogs with malignant lymphoma. <i>Transplantation</i> , 1985 , 39, 499-504 | 1.8 | 25 |
| 587 | Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2010 , 148, 48-58 | 4.5 | 24 |
| 586 | Optimising the conditioning regimen for acute myeloid leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2009 , 22, 543-50 | 4.2 | 24 |
| 585 | Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. <i>Haematologica</i> , 2012 , 97, 739-42 | 6.6 | 24 |
| 584 | Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2013 , 6, 547-62 | 2.8 | 23 |
| 583 | Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. <i>Cancer</i> , 2012 , 118, 2411-9 | 6.4 | 23 |
| 582 | Increased AF1q gene expression in high-risk myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2005 , 128, 218-20 | 4.5 | 23 |
| 581 | Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2013 , 26, 279-84 | 4.2 | 22 |
| 580 | Bone marrow transplantation in canine GM1 gangliosidosis. <i>Clinical Genetics</i> , 1990 , 38, 274-80 | 4 | 22 |
| 579 | Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial. <i>Leukemia Research</i> , 1995 , 19, 605-12 | 2.7 | 22 |
| 578 | Association of Distance from Transplantation Center and Place of Residence on Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1319-1323 | 4.7 | 22 |
| 577 | Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. <i>Leukemia</i> , 2018 , 32, 2352-2362 | 10.7 | 21 |
| 576 | Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2014 , 164, 245-50 | 4.5 | 21 |
| 575 | Success of allogeneic marrow transplantation for children with severe aplastic anaemia. <i>British Journal of Haematology</i> , 2012 , 158, 120-8 | 4.5 | 21 |
| 574 | Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia. <i>Cancer Research</i> , 2009 , 69, 185-92 | 10.1 | 21 |
| 573 | Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML). <i>Best Practice and Research in Clinical Haematology</i> , 2008 , 21, 85-92 | 4.2 | 21 |

| | | | |
|-----|--|------|----|
| 572 | Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial. <i>Lancet Haematology,the</i> , 2016 , 3, e330-9 | 14.6 | 21 |
| 571 | Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemia. <i>Cancer</i> , 2015 , 121, 2900-8 | 6.4 | 20 |
| 570 | A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). <i>Blood Advances</i> , 2020 , 4, 1683-1689 | 7.8 | 20 |
| 569 | Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. <i>Leukemia Research</i> , 2014 , 38, 329-33 | 2.7 | 20 |
| 568 | Allogeneic hematopoietic cell transplantation with full-intensity conditioning for adult acute lymphoblastic leukemia: results from a single center, 1998-2006. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1187-95 | 4.7 | 20 |
| 567 | Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 799-806 | 4.7 | 20 |
| 566 | Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis. <i>Leukemia Research</i> , 2001 , 25, 23-32 | 2.7 | 20 |
| 565 | A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2000 , 24, 183-7 | 2.7 | 20 |
| 564 | Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2001 , 7, 163-70 | 4.7 | 20 |
| 563 | Facilitation of engraftment of DLA-nonidentical marrow by treatment of recipients with monoclonal antibody directed against marrow cells surviving radiation. <i>Transplantation</i> , 1987 , 44, 607-13 ^{1.8} | 1.8 | 20 |
| 562 | ⁶⁷ Ga radionuclide imaging in Burkitt's lymphoma. <i>Radiology</i> , 1975 , 117, 639-45 | 20.5 | 20 |
| 561 | Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia. <i>Haematologica</i> , 2015 , 100, 331-5 | 6.6 | 19 |
| 560 | Responsibility for costs associated with clinical trials. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3357-9 | 2.2 | 19 |
| 559 | Hematopoietic cell transplantation in first complete remission versus early relapse. <i>Best Practice and Research in Clinical Haematology</i> , 2006 , 19, 333-9 | 4.2 | 19 |
| 558 | Allogeneic marrow transplantation and the use of hematopoietic growth factors. <i>Stem Cells</i> , 1995 , 13, 344-50 | 5.8 | 19 |
| 557 | Adhesion Of Acute Myeloid Leukemia Blasts To E-Selectin In The Vascular Niche Enhances Their Survival By Mechanisms Such As Wnt Activation. <i>Blood</i> , 2013 , 122, 61-61 | 2.2 | 19 |
| 556 | Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and Marrow Transplant Clinical | 4.7 | 18 |
| 555 | Trials Network #1102 study rationale, design, and methods. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 566-75 | 4.7 | 18 |
| 555 | Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥60 years with B cell lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 770-5 | 4.7 | 18 |

| | | | |
|-----|---|------|----|
| 554 | Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia. <i>Haematologica</i> , 2013 , 98, 114-8 | 6.6 | 18 |
| 553 | What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)?. <i>Best Practice and Research in Clinical Haematology</i> , 2008 , 21, 667-75 | 4.2 | 18 |
| 552 | Graft-versus-host disease: a surge of developments. <i>PLoS Medicine</i> , 2007 , 4, e198 | 11.6 | 18 |
| 551 | Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500). <i>American Journal of Hematology</i> , 2007 , 82, 1056-62 | 7.1 | 18 |
| 550 | 131I-Anti-CD45 Antibody Plus Fludarabine, Low-Dose Total Body Irradiation and Peripheral Blood Stem Cell Infusion for Elderly Patients with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).. <i>Blood</i> , 2005 , 106, 397-397 | 2.2 | 18 |
| 549 | Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: The Eastern Cooperative Oncology Group Experience.. <i>Blood</i> , 2005 , 106, 546-546 | 2.2 | 18 |
| 548 | Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. <i>Blood</i> , 2002 , 100, 1910-2 | 2 | 18 |
| 547 | Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 373-8 | 4.7 | 17 |
| 546 | Alternative donor transplantation for adults with acute leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2014 , 27, 272-7 | 4.2 | 17 |
| 545 | Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis. <i>Blood</i> , 2011 , 117, 7185 | 2.2 | 17 |
| 544 | Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). <i>Leukemia Research</i> , 2018 , 67, 17-20 | 2.7 | 16 |
| 543 | Hematopoietic cell transplantation for non-Hodgkin's lymphoma: yesterday, today, and tomorrow. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2927-9 | 2.2 | 16 |
| 542 | Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1409-14 | 1.9 | 16 |
| 541 | Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. <i>Blood</i> , 2016 , 128, 216-216 | 2.2 | 16 |
| 540 | Identification of differentially methylated markers among cytogenetic risk groups of acute myeloid leukemia. <i>Epigenetics</i> , 2015 , 10, 526-35 | 5.7 | 15 |
| 539 | G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm. <i>American Journal of Hematology</i> , 2015 , 90, 295-300 | 7.1 | 15 |
| 538 | A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1308-15 | 4.7 | 15 |
| 537 | Selection of patients with Hodgkin's disease and non-Hodgkin's lymphoma for bone marrow transplantation. <i>International Journal of Cell Cloning</i> , 1986 , 4 Suppl 1, 94-106 | | 15 |

| | | | |
|-----|--|------|----|
| 536 | Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2009 , 114, 536-536 | 2.2 | 15 |
| 535 | Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. <i>Leukemia</i> , 2021 , 35, 2539-2551 | 10.7 | 15 |
| 534 | Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI. <i>Haematologica</i> , 2016 , 101, e284-6 | 6.6 | 15 |
| 533 | Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 749-56 | 4.7 | 14 |
| 532 | Dose rate-dependent marrow toxicity of TBI in dogs and marrow sparing effect at high dose rate by dose fractionation. <i>Biology of Blood and Marrow Transplantation</i> , 1999 , 5, 155-61 | 4.7 | 14 |
| 531 | Chronic myelogenous leukemia. Prolonged survival with spontaneous decline in the frequency of Ph1-positive cells and subsequent development of mixed Ph1-positive and Ph1-negative blast crisis. <i>Cancer</i> , 1983 , 51, 149-53 | 6.4 | 14 |
| 530 | Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117. <i>Blood</i> , 2015 , 126, 908-908 | 2.2 | 14 |
| 529 | Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3328-3339 | 2.2 | 14 |
| 528 | Impact of allogeneic hematopoietic cell transplantation on the outcome of older patients with acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2017 , 30, 320-326 | 4.2 | 13 |
| 527 | Hematopoietic Cell Transplantation after Solid Organ Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 2123-2128 | 4.7 | 13 |
| 526 | Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia. <i>Acta Haematologica</i> , 2016 , 136, 210-218 | 2.7 | 13 |
| 525 | Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17). <i>Medical Oncology</i> , 2012 , 29, 2095-101 | 3.7 | 13 |
| 524 | Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts. <i>Blood</i> , 2008 , 111, 4813-6 | 2.2 | 13 |
| 523 | Hematopoietic cell transplantation from unrelated donors for treatment of patients with acute myeloid leukemia in first complete remission. <i>Best Practice and Research in Clinical Haematology</i> , 2007 , 20, 67-75 | 4.2 | 13 |
| 522 | Allogeneic stem cell transplantation for relapsed and refractory acute myeloid leukemia patients with 11q23 abnormalities. <i>Leukemia Research</i> , 2000 , 24, 481-6 | 2.7 | 13 |
| 521 | The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemia. <i>PLoS ONE</i> , 2013 , 8, e70812 | 3.7 | 13 |
| 520 | Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020 , 4, 4945-4954 | 7.8 | 13 |
| 519 | Uses and Growth of Hematopoietic Cell Transplantation | | 12 |

| | | | |
|-----|--|-----------|----|
| 518 | Stem-cell transplantation for myelofibrosis. <i>New England Journal of Medicine</i> , 2001 , 344, 775-6 | 59.2 | 12 |
| 517 | Post therapy imaging in high dose I-131 radioimmunotherapy patients. <i>Medical Physics</i> , 1994 , 21, 1157-62. | 4.4 | 12 |
| 516 | Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 6-20 | | 12 |
| 515 | Lung Injury Following Hematopoietic Cell Transplantation | 1456-1472 | 12 |
| 514 | Generic immunosuppressants in hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 285-90 | 4.7 | 11 |
| 513 | Preparative regimens and ageism. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1419-20 | 4.7 | 11 |
| 512 | Cord Blood Hematopoietic Cell Transplantation | 559-576 | 11 |
| 511 | Benchmarks in clinical productivity: a national comprehensive cancer network survey. <i>Journal of Oncology Practice</i> , 2007 , 3, 2-8 | 3.1 | 11 |
| 510 | Three-color versus four-color multiparameter cell cycle analyses of primary acute myeloid leukemia samples. <i>Cytometry</i> , 2000 , 42, 83-94 | | 11 |
| 509 | Cyclic neutropenia as a premalignant manifestation of acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 1986 , 22, 9-16 | 7.1 | 11 |
| 508 | Infusion of a Non HLA-Matched Off-the-Shelf Ex Vivo Expanded Cord Blood Progenitor Cell Product Following Myeloablative Cord Blood Transplantation Is Safe, Decreases the Time to Hematopoietic Recovery, and Results in Excellent Overall Survival. <i>Blood</i> , 2014 , 124, 46-46 | 2.2 | 11 |
| 507 | Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1045-1052 | 4.7 | 11 |
| 506 | Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML. <i>Leukemia</i> , 2020 , 34, 1577-1587 | 10.7 | 10 |
| 505 | Anti-T cell antibodies as part of the preparative regimen in hematopoietic cell transplantation--a debate. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, S111-5 | 4.7 | 10 |
| 504 | Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype. <i>Haematologica</i> , 2011 , 96, 631-2 | 6.6 | 10 |
| 503 | Hemopoietic stem cell transplantation for myelodysplastic syndrome. <i>Current Opinion in Oncology</i> , 2000 , 12, 116-20 | 4.2 | 10 |
| 502 | The use of colony stimulating factors in marrow transplantation. <i>Cancer</i> , 1993 , 72, 3387-92 | 6.4 | 10 |
| 501 | A Phase II Trial of 90Y-Ibritumomab Tiuxetan-Based Reduced Intensity Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation for Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma (NHL).. <i>Blood</i> , 2006 , 108, 316-316 | 2.2 | 10 |

| | | | |
|-----|--|------|----|
| 500 | Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. <i>Leukemia</i> , 2021 , 35, 2076-2085 | 10.7 | 10 |
| 499 | Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Blood Advances</i> , 2020 , 4, 611-616 | 7.8 | 10 |
| 498 | Manifestations and Treatment of Acute Graft-Versus-Host Disease 1287-1303 | | 10 |
| 497 | Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. <i>Leukemia Research</i> , 2016 , 42, 68-74 | 2.7 | 9 |
| 496 | Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. <i>Haematologica</i> , 2015 , 100, e409-11 | 6.6 | 9 |
| 495 | Autologous bone marrow transplantation in adults with non-Hodgkin's lymphoma: a Southwest Oncology Group study. <i>Hematological Oncology</i> , 1994 , 12, 75-85 | 1.3 | 9 |
| 494 | Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021 , 5, 504-512 | 7.8 | 9 |
| 493 | Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). <i>Blood Advances</i> , 2018 , 2, 1705-1718 | 7.8 | 9 |
| 492 | Long-term survival after chemotherapy for acute myeloid leukemia: the experience of the Southwest Oncology Group. <i>Cancer</i> , 1997 , 80, 2199-204 | 6.4 | 9 |
| 491 | Uses and Growth of Hematopoietic Cell Transplantation 9-15 | | 9 |
| 490 | Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials. <i>Cancer</i> , 2017 , 123, 2472-2481 | 6.4 | 8 |
| 489 | Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With IKZF3 Deletion and TP53 Mutation: Comparison With Pediatric Patients. <i>American Journal of Clinical Pathology</i> , 2015 , 144, 263-70 | 1.9 | 8 |
| 488 | Maintenance therapy after allogeneic hematopoietic cell transplantation for acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2019 , 32, 101109 | 4.2 | 8 |
| 487 | Dose intensity of preparative regimens for acute myeloid leukemia - one-size-fits-all or tailor-made?. <i>Best Practice and Research in Clinical Haematology</i> , 2010 , 23, 509-17 | 4.2 | 8 |
| 486 | Hematopoietic cell transplantation as a form of immunotherapy. <i>International Journal of Hematology</i> , 2002 , 75, 222-7 | 2.3 | 8 |
| 485 | The role of radioimmunotherapy in bone marrow transplantation. <i>Current Opinion in Hematology</i> , 1996 , 3, 438-45 | 3.3 | 8 |
| 484 | Recombinant granulocyte-macrophage colony stimulating factor followed by immunosuppressive therapy for aplastic anaemia. <i>British Journal of Haematology</i> , 1993 , 85, 182-4 | 4.5 | 8 |
| 483 | Engraftment of DLA-nonidentical bone marrow facilitated by recipient treatment with anti-class II monoclonal antibody and methotrexate. <i>Transplantation</i> , 1987 , 44, 340-5 | 1.8 | 8 |

| | | | |
|-----|--|------|---|
| 482 | Quantitative Effect of Age In Predicting Empirically-Defined Treatment-Related Mortality and Resistance In Newly Diagnosed AML: Case Against Age Alone as Primary Determinant of Treatment Assignment. <i>Blood</i> , 2010 , 116, 2191-2191 | 2.2 | 8 |
| 481 | The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials. <i>Blood</i> , 2013 , 122, 356-356 | 2.2 | 8 |
| 480 | Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60. <i>Blood</i> , 2015 , 126, 796-796 | 2.2 | 8 |
| 479 | Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia. <i>Haematologica</i> , 2020 , 105, 1731-1737 | 6.6 | 8 |
| 478 | Chronic Graft-versus-Host Disease: Clinical Manifestations and Therapy1304-1324 | | 8 |
| 477 | Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model. <i>Clinical Cancer Research</i> , 2005 , 11, 787-94 | 12.9 | 8 |
| 476 | Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2717-2719 | 1.9 | 7 |
| 475 | Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997. <i>Leukemia</i> , 2017 , 51, 2021-7 | 1.9 | 7 |
| 474 | Indications for allogeneic hematopoietic cell transplantation for acute myeloid leukemia in the genomic era. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014 , e327-33 | 7.1 | 7 |
| 473 | Low Albumin, High Ferritin, and Thrombocytopenia Before Transplant Predict Non-Relapse Mortality (NRM) Independent of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI).. <i>Blood</i> , 2009 , 114, 651-651 | 2.2 | 7 |
| 472 | ATRA, Arsenic Trioxide (ATO), and Gemtuzumab Ozogamicin (GO) Is Safe and Highly Effective in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia (APL): Final Results of the SWOG/Alliance/ECOG S0535 Trial. <i>Blood</i> , 2016 , 128, 896-896 | 2.2 | 7 |
| 471 | Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1226-1233 | 1.9 | 7 |
| 470 | The Pathophysiology of Graft-Vs.-Host Disease353-368 | | 7 |
| 469 | Oral Complications of Hematopoietic Cell Transplantation1589-1607 | | 7 |
| 468 | Impact of residual normal metaphases in core binding factor acute myeloid leukemia. <i>Cancer</i> , 2012 , 118, 2420-3 | 6.4 | 6 |
| 467 | Studies of the use of L-leucyl-L-leucine methyl ester in canine allogeneic marrow transplantation. <i>Transplantation</i> , 1993 , 55, 1244-9 | 1.8 | 6 |
| 466 | Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody (90Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018 , 132, 1018-1018 | 2.2 | 6 |
| 465 | Southwest Oncology Group Study S0910: A Phase 2 Trial of Clofarabine/ Cytarabine/ Epratuzumab for Relapsed/ Refractory Acute Lymphocytic Leukemia.. <i>Blood</i> , 2012 , 120, 2603-2603 | 2.2 | 6 |

| | | | |
|-----|--|------|---|
| 464 | Mobilization Of Blasts and Leukemia Stem Cells by Anti-CXCR4 Antibody BMS-936564 (MDX 1338) in Patients With Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2013 , 122, 3882-3882 | 2.2 | 6 |
| 463 | A phase I/II trial of iodine-131Bositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. <i>Blood</i> , 2000 , 96, 2934-2942 | 2.2 | 6 |
| 462 | Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study. <i>Blood Advances</i> , 2020 , 4, 3302-3310 | 7.8 | 6 |
| 461 | Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia. <i>Blood</i> , 2021 , | 2.2 | 6 |
| 460 | Mechanisms and Treatment of Graft Failure 2016 , 944-958 | | 6 |
| 459 | Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. <i>Leukemia</i> , 2019 , 33, 554-558 | 10.7 | 6 |
| 458 | Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. <i>Leukemia</i> , 2019 , 33, 371-378 | 10.7 | 6 |
| 457 | Growth and Development after Hematopoietic Cell Transplantation 1608-1619 | | 6 |
| 456 | Herpes Simplex Virus Infections 1382-1387 | | 6 |
| 455 | The role of hematopoietic cell transplantation as therapy for myelodysplasia. <i>Best Practice and Research in Clinical Haematology</i> , 2011 , 24, 541-7 | 4.2 | 5 |
| 454 | Failure of a single cycle of high dose cyclophosphamide followed by intensive myeloablative therapy and autologous stem cell transplantation to improve outcome in relapsed disease. <i>Cancer</i> , 1994 , 74, 715-21 | 6.4 | 5 |
| 453 | Bone marrow transplantation for malignant lymphoma. <i>European Journal of Cancer & Clinical Oncology</i> , 1987 , 23, 263-6 | | 5 |
| 452 | Failure of anti-Ia monoclonal antibody to abrogate transfusion-induced sensitization and prevent marrow graft rejection in DLA-identical canine littermates. <i>Transplantation</i> , 1988 , 45, 505-6 | 1.8 | 5 |
| 451 | Does histologic grading of inflammation in bone marrow predict the response of aplastic anaemia patients to antithymocyte globulin therapy?. <i>British Journal of Haematology</i> , 1987 , 67, 261-6 | 4.5 | 5 |
| 450 | Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR. <i>Blood</i> , 2019 , 134, 261-261 | 2.2 | 5 |
| 449 | Preliminary Results from the North American Acute Promyelocytic Leukemia (APL) Study C9710.. <i>Blood</i> , 2006 , 108, 566-566 | 2.2 | 5 |
| 448 | Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710. <i>Blood</i> , 2011 , 118, 258-258 | 2.2 | 5 |
| 447 | Global Hematopoietic Stem Cell Transplantation (HSCT) At One Million: An Achievement Of Pioneers and Foreseeable Challenges For The Next Decade. A Report From The Worldwide Network For Blood and Marrow Transplantation (WBMT). <i>Blood</i> , 2013 , 122, 2133-2133 | 2.2 | 5 |

| | | | |
|-----|--|-----|---|
| 446 | Prediction Of CR On Reinduction In Patients With Newly Diagnosed Acute Myeloid Leukemia Given Intensive Induction Regimens: A Report From SWOG and Cleveland Clinic. <i>Blood</i> , 2013 , 122, 3924-3924 | 2.2 | 5 |
| 445 | Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. Results of the Phase III Intergroup Trial E2902. <i>Blood</i> , 2015 , 126, 1308-1308 | 2.2 | 5 |
| 444 | Cord Blood Hematopoietic Cell Transplantation 2016 , 437-455 | | 5 |
| 443 | Manifestations and Treatment of Acute Graft-versus-Host Disease 2016 , 1012-1025 | | 5 |
| 442 | Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report. <i>Biopreservation and Biobanking</i> , 2018 , 16, 42-52 | 2.1 | 5 |
| 441 | Hematopoietic Cell Transplantation for Fanconi Anemia 1483-1504 | | 5 |
| 440 | Pharmacologic Prevention of Acute Graft-Versus-Host Disease 1257-1274 | | 5 |
| 439 | Fungal Infections after Hematopoietic Cell Transplantation 1346-1366 | | 5 |
| 438 | Cytomegalovirus Infection 1367-1381 | | 5 |
| 437 | Varicella-zoster Virus Infections 1388-1409 | | 5 |
| 436 | Reprint of: Allogeneic hematopoietic cell transplantation for acute myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, S3-10 | 4.7 | 4 |
| 435 | Infections in relapsed or refractory acute myeloid leukemia patients given clofarabine+cytarabine. <i>Leukemia Research</i> , 2011 , 35, e164-6 | 2.7 | 4 |
| 434 | A History of Allogeneic Hematopoietic Cell Transplantation 1-7 | | 4 |
| 433 | The History of Autologous Hematopoietic Cell Transplantation 8-14 | | 4 |
| 432 | Myelodysplasia and myeloproliferative disorders. <i>Current Opinion in Hematology</i> , 1997 , 4, 261-7 | 3.3 | 4 |
| 431 | Microgranular Variant (M3V) of Acute Promyelocytic Leukemia (APL) Does Not Have a Worse Prognosis than Classical APL in the AtrA Era: A Report of 153 Patients Treated on Intergroup 0129 and Pethema LPA96 and LPA99.. <i>Blood</i> , 2004 , 104, 394-394 | 2.2 | 4 |
| 430 | A Phase II Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥0 Years of Age with High-Risk Relapsed or Refractory B-Cell Lymphoma.. <i>Blood</i> , 2005 , 106, 487-487 | 2.2 | 4 |
| 429 | Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia. <i>Blood</i> , 2008 , 112, 149-149 | 2.2 | 4 |

| | | | |
|-----|---|------|---|
| 428 | Impact of Pre-Transplant Minimal Residual Disease Assessed by Flow Cytometry on Outcome Following Myeloablative Hematopoietic Cell Transplantation for Patients with AML-CR1.. <i>Blood</i> , 2008 , 112, 3253-3253 | 2.2 | 4 |
| 427 | Oral Small Molecule Inhibitor of VLA-4 Overcomes Adhesion Mediated Chemotherapy Resistance of Acute Myeloid Leukemia (AML) Blasts in Vitro, without Impairment of Normal Blood Cell Recovery When Combined with Chemotherapy in Vivo. <i>Blood</i> , 2008 , 112, 858-858 | 2.2 | 4 |
| 426 | International Working Group Scores Predict Post-Transplant Outcomes In Patients with Myelofibrosis. <i>Blood</i> , 2010 , 116, 3085-3085 | 2.2 | 4 |
| 425 | Multi-Institutional Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes. <i>Blood</i> , 2011 , 118, 145-145 | 2.2 | 4 |
| 424 | Prognostic Significance Of NPM1 mutations In The Absence Of FLT3-ITD in Older Patients With AML: A SWOG Report. <i>Blood</i> , 2013 , 122, 1315-1315 | 2.2 | 4 |
| 423 | Dose Dependent Enhancement Of Neutrophil Recovery By Infusion Of Notch Ligand Ex Vivo Expanded Cord Blood Progenitors: Results Of a Multi-Center Phase I Trial. <i>Blood</i> , 2013 , 122, 297-297 | 2.2 | 4 |
| 422 | Evaluation Of Which Patients Get a Second Course Of 3+7 On Cooperative Group Trials For Newly Diagnosed Acute Myeloid Leukemia: A Report From SWOG. <i>Blood</i> , 2013 , 122, 3925-3925 | 2.2 | 4 |
| 421 | Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat. <i>Blood</i> , 2016 , 128, 1166-1166 | 2.2 | 4 |
| 420 | Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemia. <i>PLoS ONE</i> , 2015 , 10, e0118485 | 3.7 | 4 |
| 419 | Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2020 , 55, 669-672 | 4.4 | 4 |
| 418 | Consolidation chemotherapy prior to hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. <i>Best Practice and Research in Clinical Haematology</i> , 2016 , 29, 365-374 ² | 4.2 | 4 |
| 417 | The Pathophysiology of Graft-versus-Host Disease 2016 , 146-155 | | 4 |
| 416 | Gastrointestinal and Hepatic Complications 2016 , 1140-1160 | | 4 |
| 415 | Hematopoietic cell transplantation as treatment of patients with acute myeloid leukemia with measurable residual disease after consolidation therapy. <i>Best Practice and Research in Clinical Haematology</i> , 2018 , 31, 405-409 | 4.2 | 4 |
| 414 | Next-generation sequencing for measuring minimal residual disease in AML. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 473-474 | 19.4 | 4 |
| 413 | Cytomegalovirus Infection701-726 | | 4 |
| 412 | Immunological Reconstitution Following Hematopoietic Cell Transplantation853-861 | | 4 |
| 411 | Growth and Development After Hematopoietic Cell Transplantation929-943 | | 4 |

| | | | |
|-----|---|------|---|
| 410 | Pharmacologic Basis for High-dose Chemotherapy287-315 | | 4 |
| 409 | Bone Marrow and Peripheral Blood Cell Donors and Donor Registries544-558 | | 4 |
| 408 | Reduced-intensity Conditioning Followed by Hematopoietic Cell Transplantation for Hematologic Malignancies1043-1051 | | 4 |
| 407 | Gastrointestinal and Hepatic Complications1434-1455 | | 4 |
| 406 | Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia. <i>Haematologica</i> , 2015 , 100, e254-6 | 6.6 | 3 |
| 405 | Hematopoietic cell transplantation for adults with acute myeloid leukemia with minimal residual disease. <i>Best Practice and Research in Clinical Haematology</i> , 2015 , 28, 133-40 | 4.2 | 3 |
| 404 | Immune Reconstitution Following Hematopoietic Cell Transplantation 2016 , 160-169 | | 3 |
| 403 | Retrospective. E. Donnall Thomas (1920-2012). <i>Science</i> , 2012 , 338, 1163 | 33.3 | 3 |
| 402 | Improved outcomes with allogeneic hematopoietic cell transplantation. <i>Best Practice and Research in Clinical Haematology</i> , 2012 , 25, 465-71 | 4.2 | 3 |
| 401 | Identifying older patients with acute myeloid leukemia who may be candidates for reduced-intensity hematopoietic cell transplantation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 319-29; quiz 330 | 7.3 | 3 |
| 400 | Immunobiologic therapies for myelodysplastic syndrome. <i>Best Practice and Research in Clinical Haematology</i> , 2004 , 17, 653-61 | 4.2 | 3 |
| 399 | Graft-vs.-Host Disease633-664 | | 3 |
| 398 | Succinyl acetone plus methotrexate as graft-versus-host disease prophylaxis in DLA-haploidentical canine littermate marrow grafts. <i>Transplantation</i> , 1992 , 54, 947-8 | 1.8 | 3 |
| 397 | Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603). <i>Blood</i> , 2018 , 132, 435-435 | 2.2 | 3 |
| 396 | Phase II Studies of Different Schedules and Doses of the Farnesyl Transferase Inhibitor Tipifarnib (R115777, Zarnestra, NSC-702818) for Patients of Age 70 or Older with Previously Untreated Acute Myeloid Leukemia (AML): A North American Intergroup Study (S0432).. <i>Blood</i> , 2007 , 110, 440-440 | 2.2 | 3 |
| 395 | The Pitfalls of Early Publication of Data in Acute Myeloid Leukemia: A Report from the Eastern Cooperative Oncology Group (ECOG).. <i>Blood</i> , 2008 , 112, 1952-1952 | 2.2 | 3 |
| 394 | Treatment-Related Mortality and Relapse Rate from Time of Initiation of Post-Remission Therapy for Patients Receiving Allogeneic Transplantation, Autologous Transplantation or Intensive Chemotherapy: A Report from the Eastern Cooperative Oncology Group (ECOG). <i>Blood</i> , 2008 , 112, 49-49 | 2.2 | 3 |
| 393 | G-CSF Priming, Clofarabine and High Dose Cytarabine (GCLAC) for Relapsed or Refractory Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2009 , 114, 2068-2068 | 2.2 | 3 |

| | | | |
|-----|--|------|---|
| 392 | Reduced Relapse and Similar Progression-Free Survival After Double Umbilical Cord Blood Transplantation (DUCBT): Comparison of Outcomes Between Sibling, Unrelated Adult and Unrelated DUCB Hematopoietic Stem Cell (HSC) Donors.. <i>Blood</i> , 2009 , 114, 662-662 | 2.2 | 3 |
| 391 | Transplantation of Peripheral Blood Cells As Compared with Bone Marrow From HLA-Identical Related Donors Is Associated with Superior Long-Term Outcomes. <i>Blood</i> , 2011 , 118, 319-319 | 2.2 | 3 |
| 390 | Declining Rates of Treatment-Related Mortality in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Given Intensive Induction Regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA). <i>Blood</i> , 2012 , 120, 129-129 | 2.2 | 3 |
| 389 | A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients. <i>Blood</i> , 2012 , 120, 354-354 | 2.2 | 3 |
| 388 | Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After BMT. <i>Blood</i> , 2012 , 120, 4164-4164 | 2.2 | 3 |
| 387 | Efficacy and Safety Of Lower-Dose Glucocorticoids For Initial Treatment Of Acute Graft-Versus-Host Disease: A Randomized Controlled Trial. <i>Blood</i> , 2013 , 122, 703-703 | 2.2 | 3 |
| 386 | Minimal Residual Disease Does Not Impact Risk of Relapse in Myeloablative Umbilical Cord Blood Transplant Recipients: Comparison with Matched and Mismatched Unrelated Transplants. <i>Blood</i> , 2014 , 124, 2579-2579 | 2.2 | 3 |
| 385 | Role of Comorbidities in Prognostic Evaluation of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) from HLA-Mismatched (MM) and Umbilical Cord Blood (UCB) Donor Grafts. <i>Blood</i> , 2014 , 124, 2583-2583 | 2.2 | 3 |
| 384 | Survival after T-Cell Replete Haplo-Identical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor Transplant for Acute Myeloid Leukemia. <i>Blood</i> , 2014 , 124, 679-679 | 2.2 | 3 |
| 383 | Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of Graft-Versus-Host Disease: A Prospective, Randomized Trial. <i>Blood</i> , 1997 , 89, 3880-3887 | 2.2 | 3 |
| 382 | Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease. <i>Leukemia</i> , 2020 , 34, 1701-1705 | 10.7 | 3 |
| 381 | Regimen-intensity per count-recovery and hospitalization index: A new tool to assign regimen intensity for AML. <i>Cancer Medicine</i> , 2020 , 9, 6515-6523 | 4.8 | 3 |
| 380 | Uses and Growth of Hematopoietic Cell Transplantation 2016 , 8-17 | | 3 |
| 379 | Pathology of Hematopoietic Cell Transplantation 2016 , 292-332 | | 3 |
| 378 | Pharmacologic Prevention of Acute Graft-versus-Host Disease 2016 , 990-1006 | | 3 |
| 377 | Human Adenovirus, Polyomavirus, and Parvovirus Infections in Patients Undergoing Hematopoietic Stem Cell Transplantation 2016 , 1129-1143 | | 3 |
| 376 | Practice Patterns and Preferences Among Hematopoietic Cell Transplantation Clinicians. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 2092-2099 | 4.7 | 3 |
| 375 | Hematopoietic Cell Transplantation for Immunodeficiency Diseases 2016 , 1430-1442 | | 3 |

| | | | |
|-----|--|-----|---|
| 374 | T-Cell Depletion to Prevent Graft-vs.-Host Disease221-233 | | 3 |
| 373 | Cord Blood Hematopoietic Cell Transplantation550-564 | | 3 |
| 372 | Gastrointestinal and Hepatic Complications769-810 | | 3 |
| 371 | Delayed Nonmalignant Complications after Hematopoietic Cell Transplantation1620-1637 | | 3 |
| 370 | Murine Models of Graft-versus-Host Disease and Graft-versus-Tumor Effect176-187 | | 3 |
| 369 | Mobilization of Autologous Peripheral Blood Hematopoietic Cells for Cellular Therapy590-604 | | 3 |
| 368 | Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia761-774 | | 3 |
| 367 | Hematopoietic Cell Transplantation for Storage Diseases1136-1162 | | 3 |
| 366 | A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma. <i>American Journal of Hematology</i> , 2020 , 95, 775-783 | 7.1 | 2 |
| 365 | Evaluation of early discharge after hospital treatment of neutropenic fever in acute myeloid leukemia (AML). <i>Leukemia Research Reports</i> , 2013 , 2, 26-8 | 0.6 | 2 |
| 364 | The Pathophysiology of Graft-Versus-Host Disease208-221 | | 2 |
| 363 | Treatment of acute myelogenous leukemia in patients over 50 years of age with V-TAD: a Southwest Oncology Group study. <i>American Journal of Hematology</i> , 1995 , 48, 228-32 | 7.1 | 2 |
| 362 | Marrow transplantation in the treatment of patients with lymphoma. <i>Current Opinion in Oncology</i> , 1989 , 1, 47-54 | 4.2 | 2 |
| 361 | Biotherapy after marrow transplantation and the use of hematopoietic growth factors. <i>Current Opinion in Oncology</i> , 1990 , 2, 289-96 | 4.2 | 2 |
| 360 | Allogeneic bone marrow transplantation in irradiated adult rabbits. <i>Transplantation</i> , 1987 , 44, 351-4 | 1.8 | 2 |
| 359 | Nonmyeloablative Therapy and Hematopoietic Cell Transplantation for Hematologic Disorders1164-1176 | | 2 |
| 358 | Predicting Induction Toxicity with 7+3: Analysis of SWOG Trial S1203. <i>Blood</i> , 2018 , 132, 1403-1403 | 2.2 | 2 |
| 357 | 131I-Anti-CD45 Antibody Plus Busulfan/Cyclophosphamide in Matched Related Transplants for Acute Myeloid Leukemia in First Remission.. <i>Blood</i> , 2004 , 104, 813-813 | 2.2 | 2 |

| | | | |
|-----|--|-----|---|
| 356 | A Myeloablative Regimen Incorporating Radiolabeled Anti-CD45 (BC8) Antibody Followed by Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Advanced Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2004 , 104, 828-828 | 2.2 | 2 |
| 355 | Minimal Residual Disease (MRD) and Risk of Relapse in Acute Promyelocytic Leukemia (APL): Insights from the North American Intergroup Phase III Trial C9710.. <i>Blood</i> , 2006 , 108, 494-494 | 2.2 | 2 |
| 354 | Conventional and Pretargeted Radioimmunotherapy Using an Anti-Murine CD45 Monoclonal Antibody in a Syngeneic, Disseminated Murine Leukemia Model.. <i>Blood</i> , 2006 , 108, 570-570 | 2.2 | 2 |
| 353 | Outcome Following Hematopoietic Cell Transplantation for Patients with AML-CR1: Comparison between Matched-Sibling and Unrelated Allografts.. <i>Blood</i> , 2007 , 110, 330-330 | 2.2 | 2 |
| 352 | Decreased Relapse Rates without Excessive Transplant Related Mortality Following Cord Blood Transplantation (CBT): A Matched Cohort Analysis Comparing Myeloablative Cord, Matched Unrelated, and Mismatched Unrelated Donor Transplants.. <i>Blood</i> , 2008 , 112, 968-968 | 2.2 | 2 |
| 351 | Southwest Oncology Group Study S0530: A Phase 2 Trial of Clofarabine/ Cytarabine for Relapsed/ Refractory Acute Lymphocytic Leukemia.. <i>Blood</i> , 2009 , 114, 3094-3094 | 2.2 | 2 |
| 350 | Risk Factors for the Development of Acute and National Institute of Health (NIH) Chronic Graft-Versus-Host Disease (GVHD).. <i>Blood</i> , 2009 , 114, 345-345 | 2.2 | 2 |
| 349 | A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates for Remission Induction Chemotherapy (Southwest Oncology Group Study S0605). <i>Blood</i> , 2010 , 116, 332-332 | 2.2 | 2 |
| 348 | Effect of Peripheral Blood Stem Cell (PBSC) Graft Composition on Graft Versus Host Disease (GVHD) and Mortality After Allogeneic Transplantation. <i>Blood</i> , 2010 , 116, 676-676 | 2.2 | 2 |
| 347 | Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18-80 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG. <i>Blood</i> , 2011 , 118, 2520-2520 | 2.2 | 2 |
| 346 | Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies. <i>Blood</i> , 2011 , 118, 289-289 | 2.2 | 2 |
| 345 | Interaction of Age and Comorbidities and Their Impacts on Hematopoietic Cell Transplantation (HCT) Outcomes. <i>Blood</i> , 2011 , 118, 665-665 | 2.2 | 2 |
| 344 | Impact of the Novel 5-Group Cytogenetic Risk Classification of MDS on Outcome After Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2011 , 118, 666-666 | 2.2 | 2 |
| 343 | Late Relapses Following All-Trans Retinoic Acid for Acute Promyelocytic Leukemia Are Uncommon, Respond Well to Salvage Therapy and Occur Independently of Prognostic Factors At Diagnosis: Long-Term Follow-up of North American Intergroup Study I0129. <i>Blood</i> , 2011 , 118, 83-83 | 2.2 | 2 |
| 342 | The Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact On Outcome in Acute Myeloid Leukemia. <i>Blood</i> , 2012 , 120, 1418-1418 | 2.2 | 2 |
| 341 | Minimal Residual Disease Detection By Next Generation Sequencing in Adult B-Cell Acute Lymphoblastic Leukemia (ALL) Patients Treated on SWOG Trial S0333. <i>Blood</i> , 2014 , 124, 2399-2399 | 2.2 | 2 |
| 340 | Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival. <i>Blood</i> , 2016 , 128, 1613-1613 | 2.2 | 2 |
| 339 | Genomic Subtypes of Nucleophosmin (NPM1) Mutations Are Associated with Clinical Outcome in AML - a COG and SWOG Intergroup Collaboration. <i>Blood</i> , 2016 , 128, 285-285 | 2.2 | 2 |

| | | | |
|-----|--|-----|---|
| 338 | Hematopoietic Cell Transplantation for Storage Diseases1455-1470 | | 2 |
| 337 | Hypomethylating agents as maintenance therapy following allogeneic hematopoietic cell transplantation for myeloid malignancies. <i>Best Practice and Research in Clinical Haematology</i> , 2021 , 34, 101241 | 4.2 | 2 |
| 336 | Hematopoietic Stem Cells, Regenerative Medicine, and Leukemogenesis 2016 , 25-57 | | 2 |
| 335 | Cytomegalovirus Infection 2016 , 1069-1079 | | 2 |
| 334 | Documentation of Engraftment and Characterization of Chimerism Following Hematopoietic Cell Transplantation234-242 | | 2 |
| 333 | Mechanisms of Tolerance300-323 | | 2 |
| 332 | Delayed Complications After Hematopoietic Cell Transplantation944-961 | | 2 |
| 331 | Secondary Malignancies After Hematopoietic Cell Transplantation962-977 | | 2 |
| 330 | Nutrition Support of the Hematopoietic Cell Transplant Recipient1551-1569 | | 2 |
| 329 | Neurologic Complications of Hematopoietic Cell Transplantation1653-1663 | | 2 |
| 328 | Vaccination of Allogeneic and Autologous Hematopoietic Cell Recipients1664-1670 | | 2 |
| 327 | High-dose Preparatory Regimens316-332 | | 2 |
| 326 | The Evaluation and Counseling of Candidates for Hematopoietic Cell Transplantation443-460 | | 2 |
| 325 | Psychosocial Issues in Hematopoietic Cell Transplantation488-501 | | 2 |
| 324 | Hematopoietic Cell Transplantation from Unrelated Donors675-691 | | 2 |
| 323 | Principles of Transfusion Support Before and After Hematopoietic Cell Transplantation1226-1243 | | 2 |
| 322 | Kidney and Bladder Complications of Hematopoietic Cell Transplantation1473-1486 | | 2 |
| 321 | The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900). <i>Leukemia Research</i> , 2019 , 78, 29-33 | 2.7 | 1 |

| | | | |
|-----|---|-----|---|
| 320 | Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design. <i>British Journal of Haematology</i> , 2014 , 166, 375-81 | 4.5 | 1 |
| 319 | Blood consult: monosomal karyotype acute myeloid leukemia. <i>Blood</i> , 2012 , 119, 5659-60 | 2.2 | 1 |
| 318 | Immune Reconstitution Following Hematopoietic Cell Transplantation222-231 | | 1 |
| 317 | Biology of Hematopoietic Stem and Progenitor Cells36-63 | | 1 |
| 316 | Biology of Hematopoietic Stem and Progenitor Cells69-95 | | 1 |
| 315 | Outcomes Research in Hematopoietic Cell Transplantation428-441 | | 1 |
| 314 | High Throughput Drug Screening of Leukemia Stem Cells Reveals Resistance to Standard Therapies and Sensitivity to Other Agents in Acute Myeloid Leukemia. <i>Blood</i> , 2018 , 132, 180-180 | 2.2 | 1 |
| 313 | Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study. <i>Blood</i> , 2018 , 132, 207-207 | 2.2 | 1 |
| 312 | Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603). <i>Blood</i> , 2018 , 132, 1534-1534 | 2.2 | 1 |
| 311 | Use of Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL) in an Expanded Access Setting at Our Cancer Consortium. <i>Blood</i> , 2018 , 132, 2710-2710 | 2.2 | 1 |
| 310 | Relationship between CD33 Expression, P-Glycoprotein-Mediated Drug Efflux, and Clinical Outcome in Patients Treated in Phase II Trials with Gemtuzumab Ozogamicin Monotherapy.. <i>Blood</i> , 2006 , 108, 2324-2324 | 2.2 | 1 |
| 309 | Frequent PML-RAR Mutations in Relapse Patients on Acute Promyelocytic Leukemia (APL) Intergroup Phase III Trial C9710.. <i>Blood</i> , 2006 , 108, 2342-2342 | 2.2 | 1 |
| 308 | Marqibo (Vincristine Sulfate Liposomes Injection, OPTISOME) Concentrates Vincristine in Tumor Tissue and Lymphoid Malignancy Oriented Tissues in Tumor-Bearing Mice.. <i>Blood</i> , 2007 , 110, 1403-1403 | 2.2 | 1 |
| 307 | Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2008 , 112, 2964-2964 | 2.2 | 1 |
| 306 | Influence of Residual Normal Metaphases In Patients with Monosomal Karyotype.. <i>Blood</i> , 2010 , 116, 1671-1671 | 2.2 | 1 |
| 305 | Over-Expression of Novel IRF8 Splice Variants Is Associated with a Significant Decrease In Relapse-Free Survival In Adult AML Patients.. <i>Blood</i> , 2010 , 116, 1679-1679 | 2.2 | 1 |
| 304 | A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables.. <i>Blood</i> , 2010 , 116, 3450-3450 | 2.2 | 1 |
| 303 | Reduced Intensity Conditioning (RIC) Transplantation In Acute Leukemia: The Effect of Source of Unrelated Donor Stem Cells on Outcomes. <i>Blood</i> , 2010 , 116, 908-908 | 2.2 | 1 |

| | | | |
|-----|---|-----|---|
| 302 | Impact of Pre-Transplant Comorbidities on the Rate of- and Mortality-Following Acute Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2011 , 118, 156-156 | 2.2 | 1 |
| 301 | Infusion of Buffy-coat-derived Third Party Ex Vivo Expanded Cord Blood Progenitor Cells As Supportive Care Following Clofarabine with High Dose Cytarabine and Granulocyte Colony-Stimulating Factor Priming for the Treatment of AML. <i>Blood</i> , 2011 , 118, 3640-3640 | 2.2 | 1 |
| 300 | Single-Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia (AML): Validation in Two Independent Sample Sets From ECOG and SWOG Trials. <i>Blood</i> , 2012 , 120, 2489-2489 | 2.2 | 1 |
| 299 | Who Participates in an Adult Cooperative Group Trial for Adolescent and Young Adults (AYAs)? Baseline Demographic and Psychosocial Characteristics of AYAs Enrolled On Intergroup Trial C10403 for Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2012 , 120, 3535-3535 | 2.2 | 1 |
| 298 | Impact of Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry Pre and Post Transplantation, On Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012 , 120, 592-592 | 2.2 | 1 |
| 297 | Prospective Phase II Multicenter Study of Conditioning with Treosulfan, Fludarabine and Low-Dose (2 Gy) Total Body Irradiation Followed by Hematopoietic Cell Transplantation From Related or Unrelated Donors for Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. <i>Blood</i> , 2012 , 120, 3613-3613 | 2.2 | 1 |
| 296 | Impact Of Cytarabine Dose In The Induction Regimen On The Outcome Of Patients With Newly Diagnosed Acute Myeloid Leukemia With Or Without NPM1 and/Or FLT3 Mutations: A SWOG and MD Anderson Cancer Center Report. <i>Blood</i> , 2013 , 122, 2686-2686 | 2.2 | 1 |
| 295 | A Phase I Study Of Myeloablative Radioimmunotherapy Using Iodine-131 Anti-CD45 Antibody Followed By Autologous Stem Cell Transplantation For High-Risk B-Cell and T-Cell Non-Hodgkin Lymphoma and Hodgkin Lymphoma. <i>Blood</i> , 2013 , 122, 3333-3333 | 2.2 | 1 |
| 294 | Assessment Of The Value Of a Day 14 Bone Marrow In Newly Diagnosed AML. <i>Blood</i> , 2013 , 122, 5002-5002 | 2.2 | 1 |
| 293 | Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 2569-2569 | 2.2 | 1 |
| 292 | In Utero Transplantation | | 1 |
| 291 | Histocompatibility | | 1 |
| 290 | Nursing Role in Hematopoietic Cell Transplantation | | 1 |
| 289 | Autologous Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma | | 1 |
| 288 | Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34) Defines a Very Poor Risk Leukemia Subgroup with Distinguishing Clinicopathological Features: A United States (US) Cytogenetics Intergroup Study of 62 AML and MDS Cases. <i>Blood</i> , 2004 , 104, 567-567 | 2.2 | 1 |
| 287 | Blockade of Adaptive Defensive Changes in Cholesterol Uptake and Synthesis in AML by the Addition of Pravastatin to Idarubicin + High Dose Ara-C: A Phase I Study. <i>Blood</i> , 2005 , 106, 405-405 | 2.2 | 1 |
| 286 | Long-Term Outcome of Autologous Followed by Nonmyeloablative Allografting from HLA-Identical Sibling for Multiple Myeloma (MM). <i>Blood</i> , 2007 , 110, 3029-3029 | 2.2 | 1 |
| 285 | Determinants of Fatal Bleeding during Induction Therapy for Acute Promyelocytic Leukemia in the ATRA Era. <i>Blood</i> , 2014 , 124, 948-948 | 2.2 | 1 |

| | | | |
|-----|--|-----|---|
| 284 | Prognostic Implications of the IDH1 synonymous SNP rs11554137 In Pediatric and Adult AML: a Children's Oncology Group and Southwest Oncology Group Study. <i>Blood</i> , 2010 , 116, 2737-2737 | 2.2 | 1 |
| 283 | A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma. <i>Blood</i> , 2011 , 118, 613-618 | 2.2 | 1 |
| 282 | Prediction Of Therapeutic Resistance In Adult Acute Myeloid Leukemia: Analysis Of 4,550 Newly Diagnosed Patients From MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center. <i>Blood</i> , 2013 , 122, 64-64 | 2.2 | 1 |
| 281 | Histocompatibility 2016 , 112-127 | | 1 |
| 280 | Biology of the Human Graft-versus-Tumor Response and How to Exploit It 2016 , 166-181 | | 1 |
| 279 | Generation of Definitive Engraftable Hematopoietic Stem Cells from Human Pluripotent Stem Cells 2016 , 16-26 | | 1 |
| 278 | Hematopoietic Cell Therapy for Human Immunodeficiency Virus Infection 2016 , 781-793 | | 1 |
| 277 | Oral Complications of Hematopoietic Cell Transplantation 2016 , 1242-1258 | | 1 |
| 276 | Subsequent Malignant Neoplasms After Hematopoietic Cell Transplantation 2016 , 1275-1289 | | 1 |
| 275 | Neurologic Complications of Hematopoietic Cell Transplantation 2016 , 1287-1298 | | 1 |
| 274 | Mechanisms of Tolerance 2016 , 136-149 | | 1 |
| 273 | The Experimental Basis for Hematopoietic Cell Transplantation for Autoimmune Diseases 2016 , 191-214 | | 1 |
| 272 | Documentation of Engraftment and Characterization of Chimerism After Hematopoietic Cell Transplantation 2016 , 272-282 | | 1 |
| 271 | Nursing Role in Hematopoietic Cell Transplantation 2016 , 362-374 | | 1 |
| 270 | Assessment of Quality of Life in Hematopoietic Cell Transplantation Recipients 2016 , 392-401 | | 1 |
| 269 | Hematopoietic Cell Procurement, Processing, and Transplantation 2016 , 414-424 | | 1 |
| 268 | Bone Marrow and Peripheral Blood Cell Donors and Donor Registries 2016 , 423-432 | | 1 |
| 267 | Mobilization of Peripheral Blood Hematopoietic Cells for Autologous HCT 2016 , 452-462 | | 1 |

| | | | |
|-----|---|------|---|
| 266 | Peripheral Blood Hematopoietic Cells for Allogeneic Transplantation 2016 , 460-471 | | 1 |
| 265 | Hematopoietic Cell Transplantation for Aplastic Anemia 2016 , 517-540 | | 1 |
| 264 | Autologous Hematopoietic Cell Transplantation for Systemic Light Chain (AL-) Amyloidosis 2016 , 724-741 | | 1 |
| 263 | Hematopoietic Cell Transplantation for Rare Hematologic Malignancies 2016 , 804-819 | | 1 |
| 262 | Adoptive T-cell Therapy for Malignancy in the Setting of Hematopoietic Cell Transplantation 2016 , 826-838 | | 1 |
| 261 | Hematopoietic Cell Transplantation for Thalassemia 2016 , 842-854 | | 1 |
| 260 | Hematopoietic Cell Transplantation for Fanconi Anemia 2016 , 923-946 | | 1 |
| 259 | Blood Group Incompatibilities and Hemolytic Complications of Hematopoietic Cell Transplantation 2016 , 955-962 | | 1 |
| 258 | Principles of Transfusion Support Before and After Hematopoietic Cell Transplantation 2016 , 961-979 | | 1 |
| 257 | Chronic Graft-versus-Host Disease [Clinical Manifestations and Therapy] 2016 , 1020-1039 | | 1 |
| 256 | Fungal Infections After Hematopoietic Cell Transplantation 2016 , 1057-1071 | | 1 |
| 255 | Varicella Zoster Virus Infections 2016 , 1085-1110 | | 1 |
| 254 | Lung Injury Following Hematopoietic Cell Transplantation 2016 , 1156-1172 | | 1 |
| 253 | Endocrine Complications Following Hematopoietic Cell Transplantation 2016 , 1181-1207 | | 1 |
| 252 | Common Potential Drug Interactions Following Hematopoietic Cell Transplantation 2016 , 1206-1217 | | 1 |
| 251 | Nutrition Support of the Hematopoietic Cell Transplant Recipient 2016 , 1216-1226 | | 1 |
| 250 | Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1511-1514 | 4.4 | 1 |
| 249 | Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia. <i>Leukemia</i> , 2021 , 35, 295-298 | 10.7 | 1 |

| | | |
|-----|--|---|
| 248 | Clinical Trials of Gene Marking and Gene Therapy Using Hematopoietic Stem Cells118-129 | 1 |
| 247 | Preparative Regimens and Modification of Regimen-Related Toxicities158-177 | 1 |
| 246 | Antibody Mediated Purging244-253 | 1 |
| 245 | The Experimental Basis for Hematopoietic Cell Transplantation for Autoimmune Diseases324-343 | 1 |
| 244 | Murine Models for Graft-Vs.-Host Disease344-352 | 1 |
| 243 | Overview of Hematopoietic Cell Transplantation Immunology16-30 | 1 |
| 242 | Hematopoietic Cell Donors538-549 | 1 |
| 241 | Fungal Infections After Hematopoietic Cell Transplantation683-700 | 1 |
| 240 | Herpes Simplex Virus Infections727-731 | 1 |
| 239 | Epstein-Barr Virus Infection749-756 | 1 |
| 238 | Allogeneic Transplantation for Myelodysplastic and Myeloproliferative Disorders1084-1095 | 1 |
| 237 | Hematopoietic Cell Transplantation from Unrelated Donors1132-1149 | 1 |
| 236 | Autologous Hematopoietic Cell Transplantation for Multiple Myeloma1262-1282 | 1 |
| 235 | Hematopoietic Cell Transplantation for Neuroblastoma1333-1344 | 1 |
| 234 | The Human Graft-versus-Tumor Response and How to Exploit It232-247 | 1 |
| 233 | Dendritic Cells in Hematopoietic Cell Transplantation248-263 | 1 |
| 232 | Documentation of Engraftment and Characterization of Chimerism Following Hematopoietic Cell Transplantation365-377 | 1 |
| 231 | Pathology of Hematopoietic Cell Transplantation390-405 | 1 |

| | | | |
|-----|--|-----|---|
| 230 | Assessment of Quality of Life in Hematopoietic Cell Transplantation Recipients502-514 | | 1 |
| 229 | Hematopoietic Cell Transplantation from Human Leukocyte Antigen Partially Matched Related Donors657-674 | | 1 |
| 228 | Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults791-805 | | 1 |
| 227 | Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Children806-826 | | 1 |
| 226 | Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Myeloproliferative Disorders827-844 | | 1 |
| 225 | Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia897-913 | | 1 |
| 224 | Hematopoietic Cell Transplantation for Immunodeficiency Diseases1105-1124 | | 1 |
| 223 | Vascular Access and Complications1244-1256 | | 1 |
| 222 | Oral Complications911-928 | | 1 |
| 221 | Outcome of Hematopoietic Cell Transplant from HLA-Matched Siblings Compared to a Volunteer Unrelated Donors Matched for HLA-A, B, C, DRB1, and DQB1 Alleles.. <i>Blood</i> , 2007 , 110, 170-170 | 2.2 | 0 |
| 220 | Prevalence and Clinical Implications of IDH2 R140 and R172 Mutations in Older Adults with AML: A Report From SWOG,. <i>Blood</i> , 2011 , 118, 3516-3516 | 2.2 | 0 |
| 219 | Effectiveness of allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2021 , 34, 101320 | 4.2 | 0 |
| 218 | Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial. <i>Leukemia Research</i> , 2021 , 111, 106736 | 2.7 | 0 |
| 217 | Adhesion Receptor Expression by Acute Myeloid Leukemia (AML) Bone Marrow Derived or Circulating Blasts and AML Stem Cells: The Key to Overcoming Chemoresistance.. <i>Blood</i> , 2009 , 114, 2658-2658 | 2.2 | 0 |
| 216 | Associations between complete remission and 2- to 3-year survival following 7 + 3 induction for acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1967-1972 | 1.9 | 0 |
| 215 | Pharmacologic Basis for High-dose Chemotherapy 2016 , 211-224 | | 0 |
| 214 | High-dose Preparatory Regimens 2016 , 223-234 | | 0 |
| 213 | Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approach. <i>Bone Marrow Transplantation</i> , 2021 , 56, 305-313 | 4.4 | 0 |

- 212 Measure for Measure: Measuring the Impact of Measuring Residual Disease in Acute Myeloid Leukemia. *Journal of Oncology Practice*, **2017**, 13, 481-483 3.1
- 211 Respiratory Viruses After Hematopoietic Cell Transplantation **2016**, 1112-1125
- 210 Hematopoietic Stem Cell Transplantation for Chronic Myeloid Leukemia **2016**, 545-556
- 209 A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia. *British Journal of Haematology*, **2013**, 163, 130-2 4.5
- 208 Radiotherapeutic Principles of Hematopoietic Cell Transplantation 333-350
- 207 Expansion of Hematopoietic Stem Cells 88-101
- 206 Molecular Biology of Stem Cell Renewal 64-71
- 205 Mechanisms of Tolerance 188-207
- 204 Mesenchymal Stromal Cells and Hematopoietic Cell Transplantation 102-115
- 203 Cellular Biology of Hematopoiesis 72-87
- 202 Hematopoietic Cell Transplantation for Multiple Myeloma 845-859
- 201 Does histologic grading of inflammation in bone marrow predict the response of aplastic anaemia patients to antithymocyte globulin therapy?. *British Journal of Haematology*, **2008**, 67, 261-266 4.5
- 200 Karyng about karyotyping in adult ALL. *Blood*, **2007**, 109, 3127-3127 2.2
- 199 Innovations in preparative regimens for autologous hematopoietic cell transplantation. *Biology of Blood and Marrow Transplantation*, **2005**, 11, 40-2 4.7
- 198 Autologous Graft-vs.-Host Disease 405-413
- 197 To transplant or not to transplant for adult acute myeloid leukemia: an ever-evolving decision. *Clinical Advances in Hematology and Oncology*, **2012**, 10, 655-62 0.6
- 196 Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with U.S. Population-Level Data. *Blood*, **2021**, 138, 337-337 2.2
- 195 Proteogenomic Characterization of Highly Enriched Viable Leukemic Blasts in Acute Myeloid Leukemia: A SWOG Report. *Blood*, **2021**, 138, 522-522 2.2

| | | |
|-----|---|-----|
| 194 | Very Late Antigen-4 (VLA-4) Expression by AML Blasts: Correlation of VCAM-1 Binding to Overall Survival.. <i>Blood</i> , 2005 , 106, 2365-2365 | 2.2 |
| 193 | Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).. <i>Blood</i> , 2005 , 106, 894-894 | 2.2 |
| 192 | Changes in the Pattern of Cytogenetic Aberrations with Advancing Age in Acute Myeloid (Non-APL) Leukemia: A Southwest Oncology Study (S9007).. <i>Blood</i> , 2006 , 108, 808-808 | 2.2 |
| 191 | Lack of Utility of Chimerism Studies at Day 80 after Myeloablative Hematopoietic Cell Transplantation for Acute Lymphocytic Leukemia.. <i>Blood</i> , 2006 , 108, 2959-2959 | 2.2 |
| 190 | Higher Doses of Transplanted T and B Cells Are Associated with Greater Incidence of Extensive Chronic GVHD after PBSC Transplantation from HLA-Identical Sibling Donors.. <i>Blood</i> , 2007 , 110, 1077-1077 | 2.2 |
| 189 | Inhibition of $\alpha 4 \beta 1$ Integrin Disrupts Adhesion and Enhances Chemotherapy Effect in Multiple Myeloma Cells.. <i>Blood</i> , 2007 , 110, 4805-4805 | 2.2 |
| 188 | Comparison of Chronic Graft-Versus-Host Disease Severity and Functional Status after Cord Blood, Haploidentical Related and 1-Allele Mismatched Unrelated Donor Hematopoietic Cell Transplantation. <i>Blood</i> , 2017 , 130, 73-73 | 2.2 |
| 187 | Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study. <i>Blood</i> , 2018 , 132, 1388-1388 | 2.2 |
| 186 | Predictors of 90-Day Mortality after Admission to Intensive Care Unit (ICU) in Patients with Acute Myeloid Leukemia (AML): Application of a Novel, Recently Validated AML-Specific Risk Model. <i>Blood</i> , 2018 , 132, 3986-3986 | 2.2 |
| 185 | Pre-Transplant Monocytic Myeloid-Derived Suppressor Cell Frequency Has No Prognostic Role for Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Remission. <i>Blood</i> , 2018 , 132, 5255-5255 | 2.2 |
| 184 | 2nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials. <i>Blood</i> , 2018 , 132, 3978-3978 | 2.2 |
| 183 | Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data. <i>Blood</i> , 2019 , 134, 291-291 | 2.2 |
| 182 | Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report. <i>Blood</i> , 2019 , 134, 2691-2691 | 2.2 |
| 181 | Comparative Analysis of Total Body Irradiation (TBI)-Based and Non-TBI-Based Myeloablative Conditioning for Acute Myeloid Leukemia in Remission with and without Measurable Residual Disease. <i>Blood</i> , 2019 , 134, 321-321 | 2.2 |
| 180 | Myelodysplastic Syndrome with Excess Blasts and Secondary Acute Myeloid Leukemia: Same Disease with Different Blast Count. <i>Blood</i> , 2019 , 134, 2692-2692 | 2.2 |
| 179 | Telomere Length Recovery Strongly Predicts Overall Survival in Acute Promyelocytic Leukemia. <i>Blood</i> , 2014 , 124, 2375-2375 | 2.2 |
| 178 | Effect of Allogeneic Hematopoietic Cell Transplant in First Complete Remission on Post-Relapse CR Rate and Survival in Acute Myeloid Leukemia. <i>Blood</i> , 2014 , 124, 5257-5257 | 2.2 |
| 177 | Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory AML: Analysis of 1,892 Patients from HOVON/SAKK and SWOG. <i>Blood</i> , 2014 , 124, 3676-3676 | 2.2 |

- 176 Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia. *Blood*, **2015**, 126, 3803-3803
- 175 A Phase II Trial of Radioimmunotherapy-Based Autologous Transplantation with I-131 Tositumomab, Cyclophosphamide and Etoposide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. *Blood*, **2015**, 126, 5502-5502 2.2
- 174 Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Is It Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?. *Blood*, **2015**, 126, 2571-2577
- 173 Defining the Genomic Make up of Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): Report from COG AAML03P1, AAML531 and SWOG S0106. *Blood*, **2015**, 126, 2576-2576 2.2
- 172 Significance of Peri-Transplant Dynamics of Minimal Residual Disease (MRD) in Adults with Acute Myeloid Leukemia (AML) in Morphological Remission Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. *Blood*, **2015**, 126, 173-173 2.2
- 171 Prognostic Methylation Markers for Survival in Cytogenetically Normal AML Patients Treated on SWOG Trials. *Blood*, **2015**, 126, 688-688 2.2
- 170 A Precision Medicine Approach Incorporating Both Molecular and In Vitro Functional Data to Treat Patients with Relapsed/Refractory Acute Myeloid Leukemia. *Blood*, **2016**, 128, 4043-4043 2.2
- 169 Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report. *Blood*, **2016**, 128, 2890-2890 2.2
- 168 Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients.. *Blood*, **2008**, 112, 1130-1130
- 167 Adult Cord Blood Transplantation (CBT) Vs. Unrelated Donor Transplantation: A Cost Comparison. *Blood*, **2008**, 112, 2383-2383 2.2
- 166 Nonmyeloablative Allogeneic HCT From Unrelated Donors for Multiple Myeloma (MM).. *Blood*, **2009**, 114, 3391-3391 2.2
- 165 Frequency of Allogeneic Stem Cell Transplant(SCT) in Patients Presenting with Newly-Diagnosed AML or AML at Time of First Salvage Therapy.. *Blood*, **2009**, 114, 4332-4332 2.2
- 164 Anti-CD45 Ab Pretargeted Radioimmunotherapy Using An Alpha Emitting Radionuclide (213Bi) Delivers Selective Radiation to Human Myeloid Leukemias in a Mouse Xenograft Model and Results in High Rates of Complete Remission and Long Term Survival.. *Blood*, **2009**, 114, 1035-1035 2.2
- 163 Clonal Markers In Relapsed Acute Promyelocytic Leukemia (APL): Clinicopathological Associations and Relation to All-Trans Retinoic Acid (ATRA) Treatment on Intergroup Phase III Trial C9710.. *Blood*, **2010**, 116, 1038-1038 2.2
- 162 Evaluation of Early Discharge After Hospital Treatment of Neutropenic Fever In Acute Myelogenous Leukemia (AML).. *Blood*, **2010**, 116, 3806-3806 2.2
- 161 Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997. *Blood*, **2010**, 116, 924-924 2.2
- 160 Analysis of CRLF2/JAK Expression and Mutation Status In Adult ALL Patients. *Blood*, **2010**, 116, 758-758 2.2
- 159 CD38 Status of CD34+ Myeloblasts, but Not Side Population (SP) Frequency, Predicts Initial Response to Induction Therapy In Patients with Newly Diagnosed Acute Myeloid Leukemia (AML).. *Blood*, **2010**, 116, 1056-1056 2.2

| | | |
|-----|---|-----|
| 158 | Early Discharge and Outpatient Management of Adult Patients Following Intensive Induction Chemotherapy for MDS and Non-APL AML: A Pilot Study. <i>Blood</i> , 2010 , 116, 2161-2161 | 2.2 |
| 157 | Association of Graft-Versus-Host Disease and Immunosuppressive Treatment with Risks of Recurrent Malignancy and Mortality After Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2010 , 116, 218-218 | 2.2 |
| 156 | A Retrospective Comparison of Tacrolimus Vs. Cyclosporine for Immunosuppression After Allogeneic Hematopoietic Cell Transplantation with G-CSF-Mobilized Blood Cells. <i>Blood</i> , 2010 , 116, 2319-2319 | 2.2 |
| 155 | Multivariate Analysis of Response and Survival After Treatment with Clofarabine, Cytarabine and G-CSF Priming (GCLAC) In Relapsed/Refractory Acute Myeloid Leukemia (AML): Comparison with Prior Experience Using Fludarabine and Cytarabine Combination Regimens.. <i>Blood</i> , 2010 , 116, 1065-1065 | 2.2 |
| 154 | Clinical and Functional Relevance of Interactions Between the Bone Marrow Stromal Microenvironment and Primary Human Acute Myeloid Leukemia (AML) Cells. <i>Blood</i> , 2010 , 116, 2756-2756 | 2.2 |
| 153 | Survival After Failure of Initial Therapy for Newly-Diagnosed or Relapsed/Refractory AML At An Academic Center: Subsequent Clinical Trial Vs. Not. <i>Blood</i> , 2011 , 118, 1497-1497 | 2.2 |
| 152 | Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm,. <i>Blood</i> , 2011 , 118, 3617-3617 | 2.2 |
| 151 | Response to High Dose Cytarabine (HIDAC) As First Salvage for Relapsed Acute Lymphocytic Leukemia in Patients Receiving HIDAC As Initial Therapy. <i>Blood</i> , 2011 , 118, 2594-2594 | 2.2 |
| 150 | Novel Dual E-Selectin-CXCR4 Inhibitors Mobilize Human Acute Myeloid Leukemia (AML) Cells in the NODscid IL2R β Xenograft and Confer Susceptibility to Cytarabine. <i>Blood</i> , 2011 , 118, 579-579 | 2.2 |
| 149 | Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Speed of Neutrophil and Platelet Recovery. <i>Blood</i> , 2011 , 118, 1498-1498 | 2.2 |
| 148 | KIT Mutations Are Rare Among Elderly AML Patients: A SWOG Report. <i>Blood</i> , 2011 , 118, 2510-2510 | 2.2 |
| 147 | Outcome and Prevalence of Hyperdiploidy and Hypodiploidy in Adults with Newly Diagnosed Acute Lymphocytic Leukemia: A SWOG Study. <i>Blood</i> , 2011 , 118, 2555-2555 | 2.2 |
| 146 | Impact of Comorbidities on Early and Late Mortalities After Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2011 , 118, 326-326 | 2.2 |
| 145 | DNMT3A Mutations Independently Predict Poor Outcome in Older AML Patients: A SWOG Report,. <i>Blood</i> , 2011 , 118, 3519-3519 | 2.2 |
| 144 | Identification of Differential Methylation Markers Among Cytogenetic Risk Groups of Acute Myeloid Leukemia. <i>Blood</i> , 2011 , 118, 1464-1464 | 2.2 |
| 143 | The CXCR4 Inhibitor Plerixafor Effectively Mobilizes Primary AML in NODscid IL2R β Xenografts and Markedly Reduces but Does Not Eradicate Leukemia in Combination with Cytarabine +/- Clofarabine Chemotherapy. <i>Blood</i> , 2011 , 118, 1432-1432 | 2.2 |
| 142 | Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data. <i>Blood</i> , 2011 , 118, 1446-1446 | 2.2 |
| 141 | Quantitative Significance of Minimal Residual Disease Before Myeloablative Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First and Second Complete Remission. <i>Blood</i> , 2012 , 120, 655-655 | 2.2 |

- 140 RNA-Sequencing Unveils Cryptic Fusions in Patients with Acute Myeloid Leukemia. *Blood*, **2012**, 120, 1278-1278 2.2
- 139 A Phase II Trial of Myeloablative I-131-Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Transplantation for B-Cell Non-Hodgkin's Lymphoma. *Blood*, **2012**, 120, 811-811 2.2
- 138 NCI Common Toxicity Criteria and Mortality After Chemotherapy for Acute Myeloid Leukemia (AML). *Blood*, **2012**, 120, 1479-1479 2.2
- 137 Prognostic Significance of the French-American-British (FAB) Morphologic Subclassification of Acute Myeloid Leukemia, Not Otherwise Specified in the 2008 WHO Classification: Analysis of 5,848 Newly Diagnosed Patients From HOVON, MRC/NCRI, SWOG, and MD Anderson Cancer 2.2
- 136 A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). *Blood*, **2012**, 120, 1924-1924 2.2
- 135 Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Platelet and Neutrophil Recovery.. *Blood*, **2012**, 120, 2598-2598 2.2
- 134 Myeloablative Umbilical Cord Blood Transplantation for Hematologic Malignancies Is Comparable to Unrelated Donor Transplantation: A Retrospective Single-Center Study. *Blood*, **2012**, 120, 1995-1995 2.2
- 133 Morphology Vs. Multiparameter Flow Cytometry in Evaluation of AML in Cerebrospinal Fluid (CSF).. *Blood*, **2012**, 120, 2499-2499 2.2
- 132 Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm. *Blood*, **2012**, 120, 3594-3594 2.2
- 131 A Scoring System for Prediction of FLT3-ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia.. *Blood*, **2012**, 120, 2590-2590 2.2
- 130 Safety and Efficacy of Bendamustine and Idarubicin in Combination Therapy for Patients Age \geq 60 with Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome [Results From a Phase I/II Adaptive Design Study.. *Blood*, **2012**, 120, 2622-2622 2.2
- 129 A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS). *Blood*, **2013**, 122, 3926-3926 2.2
- 128 Proof-Of-Concept Study For Precision Medicine With Chromosome Genomic Array Testing (CGAT) For Drug Sensitivity Screening In Acute Myeloid Leukemia. *Blood*, **2013**, 122, 2578-2578 2.2
- 127 NUP98/NSD1 Translocation Further Risk-Stratifies Patients With FLT3/ITD In Acute Myeloid Leukemia: A Report From Children's Oncology Group and SWOG. *Blood*, **2013**, 122, 488-488 2.2
- 126 Novel Long-Term Co-Culture Approach Identifies Prognostically Important Heterogeneity Of Stem/Progenitor Cell Involvement In Human Acute Myeloid Leukemia. *Blood*, **2013**, 122, 1318-1318 2.2
- 125 Comparison Of Minimal Residual Disease As Outcome Predictor For AML Patients In First Complete Remission Undergoing Myeloablative Or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation. *Blood*, **2013**, 122, 1317-1317 2.2
- 124 Alteration Of Cytogenetic Risk Stratification In New Diagnosis Of Leukemia By FISH Testing □ Retrospective Review Of The SWOG Experience. *Blood*, **2013**, 122, 1383-1383 2.2
- 123 Cryopreservation of Hematopoietic Cells **2016**, 469-481

- 122 A History of Allogeneic and Autologous Hematopoietic Cell Transplantation **2016**, 1-11
- 121 Marrow Microenvironment and Biology of Mobilization of Stem Cells **2016**, 50-67
- 120 Expansion of Human Hematopoietic Stem Cells **2016**, 62-70
- 119 Mesenchymal Stromal Cells and Hematopoietic Cell Transplantation **2016**, 69-79
- 118 Hematopoietic Cell Transplantation for Immunodeficiency Diseases **2016**, 866-889
- 117 Genetic Manipulation of Hematopoietic Stem Cells **2016**, 78-99
- 116 Overview of Hematopoietic Cell Transplantation Immunology **2016**, 96-114
- 115 Growth and Development After Hematopoietic Cell Transplantation **2016**, 1257-1268
- 114 Delayed Non-malignant Complications After Hematopoietic Cell Transplantation **2016**, 1266-1276
- 113 Vaccination of Allogeneic and Autologous Hematopoietic Cell Recipients **2016**, 1297-1306
- 112 Natural Killer Cells and Allogeneic Hematopoietic Cell Transplantation **2016**, 126-138
- 111 Immune Regulation in Hematopoietic Cell Transplantation **2016**, 153-162
- 110 Dendritic Cells in Hematopoietic Cell Transplantation **2016**, 178-194
- 109 Reduced-intensity Allogeneic Transplantation Regimens **2016**, 232-246
- 108 Radiotherapeutic Principles of Hematopoietic Cell Transplantation **2016**, 244-261
- 107 Radioimmunotherapy and Hematopoietic Cell Transplantation **2016**, 258-275
- 106 The Detection and Significance of Minimal Residual Disease **2016**, 281-296
- 105 Biostatistical Methods in Hematopoietic Cell Transplantation **2016**, 329-341

- 104 Outcomes Research in Hematopoietic Cell Transplantation **2016**, 341-350
- 103 The Evaluation and Counseling of Candidates for Hematopoietic Cell Transplantation **2016**, 349-365
- 102 Ethical Issues in Hematopoietic Cell Transplantation **2016**, 374-385
- 101 Psychosocial Issues in Hematopoietic Cell Transplantation **2016**, 384-393
- 100 Sexuality Following Hematopoietic Cell Transplantation **2016**, 399-408
- 99 Hematopoietic Cell Transplantation **2016**, 407-414
- 98 The Role of the Transplant Program in a Nuclear Accident or Terrorism **2016**, 431-437
- 97 Use of Recombinant Growth Factors after Hematopoietic Cell Transplantation **2016**, 480-491
- 96 Hematopoietic Cell Transplantation from Human Leukocyte Antigen Partially Matched Related Donors **2016**, 489-508
- 95 Hematopoietic Cell Transplantation from Unrelated Donors **2016**, 505-520
- 94 Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria **2016**, 537-546
- 93 Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia **2016**, 554-565
- 92 Hematopoietic Cell Transplantation for Childhood Acute Myeloid Leukemia **2016**, 576-590
- 91 Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults **2016**, 588-601
- 90 Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Children **2016**, 600-617
- 89 Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms **2016**, 613-627
- 88 Hematopoietic Cell Transplantation for Multiple Myeloma **2016**, 625-639
- 87 Hematopoietic Cell Transplantation for Hodgkin Disease **2016**, 675-695

- 86 Hematopoietic Cell Transplantation for Non'Hodgkin Lymphoma (B Cell) **2016**, 692-705
- 85 Hematopoietic Cell Transplantation for Non'Hodgkin Lymphoma (T Cell) **2016**, 703-716
- 84 Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia **2016**, 714-726
- 83 Autologous Hematopoietic Cell Transplantation for Breast Cancer and Germ-cell Tumors **2016**, 739-750
- 82 Hematopoietic Cell Transplantation for Renal Cell Carcinoma and Other Solid Tumors **2016**, 748-761
- 81 Hematopoietic Cell Transplantation for Neuroblastoma **2016**, 760-770
- 80 Hematopoietic Cell Transplantation for Other Pediatric Solid Tumors **2016**, 768-784
- 79 Hematopoietic Cell Transplantation for Autoimmune Diseases **2016**, 792-806
- 78 Adoptive T-cell Therapy for Viral Disease in the Setting of Hematopoietic Cell Transplantation **2016**, 816-827
- 77 Relapse of Hematologic Malignancy After Allogeneic Hematopoietic Transplantation **2016**, 836-844
- 76 Hematopoietic Cell Transplantation for Sickle Cell Disease **2016**, 853-868
- 75 Hematopoietic Cell Transplantation for Storage Diseases **2016**, 885-912
- 74 Hematopoietic Cell Transplantation for Macrophage, Granulocyte and Osteoclast Disorders **2016**, 910-925
- 73 Vascular Access and Complications **2016**, 976-991
- 72 T-cell Depletion to Prevent Graft-versus-Host Disease **2016**, 1004-1014
- 71 Herpes Simplex Virus Infections **2016**, 1078-1086
- 70 EpsteinBarr Virus Infection **2016**, 1105-1113
- 69 HHV-6A, HHV-6B, HHV-7, and HHV-8 After Hematopoietic Cell Transplantation **2016**, 1122-1131

- 68 Kidney and Bladder Complications of Hematopoietic Cell Transplantation **2016**, 1170-1184
- 67 Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203. *Leukemia and Lymphoma*, **2021**, 62, 1774-1777 1.9
- 66 VENOCCLUSIVE DISEASE OF THE LIVER AFTER CHEMORADIOTHERAPY AND AUTOLOGOUS BONE MARROW TRANSPLANTATION1. *Transplantation*, **1987**, 43, 870-873 1.8
- 65 Methods for Gene Transfer: Genetic Manipulation of Hematopoietic Stem Cells107-117
- 64 AIDS and Hematopoietic Transplantation: HIV Infection, AIDS, Lymphoma and Gene Therapy1369-1384
- 63 Marrow Transplantation in Thalassemia1407-1416
- 62 Pharmacologic Basis for High-Dose Chemotherapy130-157
- 61 Radiotherapeutic Principles of Hematopoietic Cell Transplantation178-197
- 60 Molecular Inhibition of Gene Expression in Hematopoietic Cells258-271
- 59 The Detection and Significance of Minimal Residual Disease272-285
- 58 Pathology of Hematopoietic Cell Transplantation286-299
- 57 Adoptive Immunotherapy With Antigen-Specific T Cells380-404
- 56 The Evaluation and Counseling of Candidates for Hematopoietic Cell Transplantation447-462
- 55 Clinical and Administrative Support for Hematopoietic Cell Transplant Programs463-468
- 54 Nursing Issues in Hematopoietic Cell Transplantation469-482
- 53 Psychosocial Issues in Hematopoietic Cell Transplantation497-506
- 52 Histocompatibility31-42
- 51 Hematopoietic Cell Procurement, Processing and Transplantation: Regulation and Accreditation529-537

- 50 In Utero Transplantation 565-575
- 49 Mobilization of Autologous Peripheral Blood Hematopoietic Cells for Support of High-Dose Cancer Therapy 576-587
- 48 Recombinant Growth Factors After Hematopoietic Cell Transplantation 613-623
- 47 The Hematopoietic Microenvironment 53-61
- 46 Nutritional Support of Hematopoietic Cell Recipients 883-893
- 45 Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia 979-1001
- 44 Allogeneic Hematopoietic Cell Transplantation for Adult Patients With Acute Myeloid Leukemia 1025-1039
- 43 Allogeneic Transplantation for Acute Myeloid Leukemia in Children 1040-1054
- 42 Allogeneic Transplantation for Acute Lymphoblastic Leukemia in Children 1067-1083
- 41 Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma 1096-1104
- 40 Allogeneic Transplantation for Lymphoma and Chronic Lymphocytic Leukemia 1105-1115
- 39 Hematopoietic Cell Transplantation from HLA Partially Matched Related Donors 1116-1131
- 38 Allogeneic Hematopoietic Cell Transplantation for Solid Tumors 1177-1187
- 37 Autologous and Allogeneic Hematopoietic Cell Transplantation for Hodgkin's Disease 1189-1206
- 36 Autologous Hematopoietic Cell Transplantation for Acute Myeloid Leukemia 1221-1237
- 35 Expansion of Hematopoietic Stem Cells 96-106
- 34 Autologous Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia 1250-1261
- 33 Autologous Hematopoietic Cell Transplantation for AL Amyloidosis 1283-1297

- 32 Hematopoietic Cell Transplantation in Germ Cell Tumors1308-1319
- 31 Hematopoietic Cell Transplantation for Brain Tumors1345-1353
- 30 Hematopoietic Cell Transplantation for Pediatric Patients With Solid Tumors1354-1368
- 29 Genetic Manipulation of Hematopoietic Stem Cells116-128
- 28 Critical Care of the Hematopoietic Cell Transplant Recipient1539-1550
- 27 Secondary Malignancies after Hematopoietic Cell Transplantation1638-1652
- 26 Natural Killer Cells and Allogeneic Hematopoietic Cell Transplantation163-175
- 25 Radioimmunotherapy and Hematopoietic Cell Transplantation351-364
- 24 The Detection and Significance of Minimal Residual Disease376-389
- 23 Biostatistical Methods in Hematopoietic Cell Transplantation406-427
- 22 Hematopoietic Cell Procurement, Processing, and Transplantation: Standards, Accreditation, and Regulation533-543
- 21 Generation of Definitive Engraftable Hematopoietic Stem Cells from Human Embryonic Stem Cells23-35
- 20 Use of Recombinant Growth Factors after Hematopoietic Cell Transplantation645-656
- 19 Hematopoietic Cell Transplantation for Aplastic Anemia705-726
- 18 Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia751-760
- 17 Hematopoietic Cell Transplantation for Childhood Acute Myeloid Leukemia775-790
- 16 Hematopoietic Cell Transplantation for Hodgkin's Disease860-877
- 15 Non-Hodgkin's Lymphoma878-896

- 14 Autologous Hematopoietic Cell Transplantation for Systemic Light Chain (AL-) Amyloidosis914-930
- 13 Hematopoietic Cell Transplantation for Breast Cancer931-947
- 12 Hematopoietic Cell Transplantation in Germ Cell Tumors948-957
- 11 Hematopoietic Cell Transplantation for Renal Cell and other Solid Tumors958-959
- 10 Hematopoietic Cell Transplantation for Neuroblastoma970-984
- 9 Hematopoietic Cell Transplantation for Other Pediatric Solid Tumors985-1000
- 8 Hematopoietic Cell Transplantation for Patients with Human Immunodeficiency Virus Infection1001-1013
- 7 Hematopoietic Cell Transplantation for Rare Hematologic Malignancies1030-1042
- 6 Management of Relapse after Hematopoietic Cell Transplantation1059-1075
- 5 Hematopoietic Cell Transplantation for Thalassemia1077-1089
- 4 Hematopoietic Cell Transplantation for Fanconi's Anemia1178-1199
- 3 Mechanisms and Treatment of Graft Failure1201-1218
- 2 EpsteinBarr Virus Infection1410-1418
- 1 Common Potential Drug Interactions Following Hematopoietic Cell Transplantation1523-1538